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ABSTRACT
Arginine vasopressin (AVP) is a 9 amino acid, posterior pituitary, peptide hormone that 
plays a pivotal role in both salt and water homeostasis and blood pressure control. These 
effects are mediated primarily through 2  main receptor types; the former through the renal 
tubular V2  receptor (V2R) and the later the smooth muscle cell Via receptor (ViaR). AVP 
has received little attention since its discovery in 1885 and the precise actions of this 
hormone in both physiology and disease often remains unclear. Recent research has 
brought to light that AVP does have a number of actions relevant to the progression of 
cardiovascular diseases (CVDs) and that the AVP receptors are often differentially 
regulated in a number of these conditions. Fully understanding what these changes are, 
and how they contribute to CVDs, will open doors for the development of new therapeutic 
agents to ultimately help reduce morbidity and mortality within our populations.
The aims of this thesis were threefold.
1. To fully characterise in vitro 5 novel AVP receptor antagonists (drugs A-E) and from 
these to select the single most promising agent and undertake further in vitro and in vivo 
study.
2. To investigate the possibility of additive cardiovascular benefits of ACE inhibition with 
V iaR antagonism in an adult, hypertensive rat model.
3. To examine the regulation of AVP and its ViaRs in a hypertensive rat model with 8  
weeks of streptozocin induced diabetes mellitus (STZ-DM).
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Within an in vitro experimental setting, drugs A-E displaced specific Via and V2R 
antagonists in a dose-dependent manner. Drug A most closely resembled AVP in this 
regard and was thus selected for further in vitro and in vivo study. A dose of 1 Omg/kg was 
found to be effective acutely with maximal receptor inhibition at 2 hours. Significant 
inhibition was seen for 4 hours at the ViaR and 8  hours at the V2 R. When administered in 
a chronic 5 day setting to normotensive rats, systolic blood pressure (SBP) remained 
unaltered and a diminishing aquaresis was seen.
In experimental, adult, genetic hypertension, 2 weeks of administration of the ViAR 
antagonist OPC 21268 did not have any antihypertensive benefits while the ACE inhibitor, 
ramipril, and combination treatment with ramipril and OPC 21268 lowered SBP to the 
same extent. Likewise, only the ramipril treated animals demonstrated any reductions in 
cardiac weights. These results imply that ViaR antagonism does not have a role to play in 
combating established genetic hypertension in the 2  week setting but does not rule out any 
longer term structural benefits that may come to light in the context of a more prolonged 
study.
In the setting of 8  weeks of experimental, hypertensive STZ-DM, AVP was elevated with 
hepatic and renal ViaRs being up-regulated in association with this. This up-regulation 
was in terms of receptor numbers only (Bmax), as receptor affinity (Kd) remained 
unaltered when compared to hypertensive non-diabetic controls. Interestingly, the 
corresponding receptor mRNA levels were not elevated raising the possibility of a post- 
transcriptional effect. This is the first study to demonstrate an up-regulation of the AVP 
receptor system in the context of hypertension and DM.
AVP, via stimulation of its Via and V2R.S, elicits important biological actions that have 
been shown to contribute to the pathophysiology of many forms of CVDs such as 
hypertension and DM. Therapeutic agents to block the AVP receptor are constantly being 
developed and assessed. In order to determine its ultimate clinical usefulness Drug A 
should now undergo further trials in disease models such as cardiac failure and low renin 
hypertension, a category of hypertension seen mainly in the elderly, African-American and 
diabetic populations where AVP has been shown to play a more prominent pathological 
role. It has been shown in this thesis that the AVP ViaR system is up-regulated in DM 
combined with hypertension. Consequently, AVP ViAR blockade provides an exciting 
new potential therapeutic target that could play an integral role in any future treatment 
strategies to help combat the ongoing 
epidemic of this cardiovascular disease.
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Chapter 1: Literature review 4
1.1 INTRODUCTION
Diseases such as hypertension and diabetes mellitus (DM) are among the leading causes of 
morbidity and mortality in developed countries (1-4). Their prevalence is rapidly 
escalating and associated spiralling health care costs places huge economic burdens on 
government resources that ultimately impacts on society (5). A number of therapeutic 
strategies already exist for the treatment of hypertension and these include the use of 
diuretics, beta blockers, calcium channel antagonists and angiotensin-converting enzyme 
(ACE) inhibitors (6 , 7). To improve the efficacy of ACE inhibitors in low renin forms of 
essential hypertension, such as that seen in the diabetic, elderly or African-American 
populations, it is common clinical practice to co-prescribe a diuretic (8 , 9). This is 
undoubtedly efficacious but does carry with it associated metabolic disturbances that can 
be problematic, particularly in the elderly (8 ). ACE inhibitors have also proven to be the 
single most useful treatment in the diabetic patient, considerably reducing both 
macrovascular and microvascular complications (10, 11). Hypertension is a common co­
morbidity factor in these patients (12-14). Despite the advent of ACE inhibition, mortality 
and morbidity rates in this disease remain unacceptably high (4, 15) and alternative 
therapeutic strategies, that may provide additional benefits, are continually being sought.
Two very similar cyclic, 9 amino acid, posterior pituitary hormones exist -  arginine 
vasopressin (AVP) and oxytocin. These substances are synthesised in the hypothalamic 
nuclei that are connected to the neurohypophysis. Oxytocin acts on the breast to cause milk 
ejection and on the pregnant myometrium to cause contraction and expulsion of the foetus 
in labour. In large amounts oxytocin has some AVP-like activity. This thesis has 
examined the role of AVP and its receptors in experimental models of cardiovascular 
disease (CVD) and a review of the oxytocin system will not be done here.
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In 1895 Oliver and Shafer first discovered the neurohormone arginine vasopressin (AVP) 
when they intravenously (IV) injected posterior pituitary extracts into dogs and noticed an 
increase in blood pressure (BP) (16). From this experiment they named the presumptive 
active substance in the posterior pituitary extracts vasopressin. Subsequent studies 
revealed that AVP also acted as a potent anti-diuretic (17) and for many years to come the 
renal water-sparing action of this hormone was the main focus of any research. Only in 
relatively recent times have the cardiovascular aspects of AVP received attention and 
research into this has become increasingly prolific since the advent of specific antagonists 
to AVP receptors (18).
AVP is a 9 amino acid neurohormone that plays a pivotal role in salt and water 
homeostasis and BP regulation via activation of its receptor subtypes classified as Vi and 
V2. The Vi receptor (ViR) is further subclassified into Via and Vib (or V3). Interaction of 
AVP with the VjR leads to cell membrane phospholipase activation and mobilisation of 
intracellular calcium to cause vasoconstriction (19, 20) while interaction with the V2  
receptor (V2R) leads to activation of adenylyl cyclase (AC) and production of cyclic 
adenosine monophosphate (cAMP) that ultimately causes antidiuresis (21, 22). The V2R 
has only conclusively been demonstrated thus far in the kidney (see section 1.3.3.3). The 
ViaR has a more widespread distribution being found in liver, platelets, blood vessels, 
testes and brain to name but a few (see section 1.3.2.3) while the Vib receptor (VibR) has 
been localised in the anterior pituitary, various regions of the rat brain and human adrenal 
medulla, as well as more recently been found to be abundant within the pancreas (see 
section 1.3.4.3).
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Several lines of evidence indicate that AVP may contribute to the progression of CVD. 
Firstly, elevated plasma levels of AVP are found in DM (23-25), congestive cardiac failure 
(CCF) (26) and in some forms of hypertension (27-29). Secondly, AVP has mitogenic and 
hyperplastic actions that, by analogy to angiotensin II (Ang II), may have deleterious 
effects when present in chronic excess (30, 31). Thirdly, there is evidence that AVP is 
synthesised, not only in the hypothalamus of the brain where it acts systemically, but also 
locally in blood vessels and the heart where it may function as a paracrine/autocrine 
hormone (32-36).
Over the past decade AVP research has become particularly prolific as orally active, non­
peptide, selective Via and V2 R antagonists have become available. This has allowed 
various research groups to assess more easily the role of AVP in CVDs. (37-41). Orally 
effective and selective AVP receptor antagonists, such as OPC 21268 and SR49059, block 
the pressor effects of AVP at the ViaR (28, 42) while V2 R antagonists such as OPC 31260 
(41, 43), OPC 41061 (44) and SR121463A (45) cause aquaresis. Dual Via and V2R 
blockers such as YM087 (46) have also recently become available and are currently the 
subject of intensive research while more recently still a selective VibR non-peptide 
antagonist, SSR149415, has entered the arena and now represents a unique tool for 
exploring the functional role of the VibR, a task that has hitherto been extremely difficult 
(47). Intense research is currently ongoing to develop new, non-peptide Via, V2  and in 
particular dual V 1A/V2 R blockers. In contrast to diuretics, AVP receptor antagonists lack 
undesirable associated metabolic disturbances and may in addition have other beneficial 
effects such as antihypertrophic and antiproliferative actions. These properties make AVP 
receptor antagonists an attractive additional therapy to ACE inhibition in the treatment of 
CVDs.
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In the developmental phase of experimental hypertension, in the spontaneously 
hypertensive rat (SHR), ViaR antagonist, in a similar way to ACE inhibition (48), 
attenuates the progression of hypertension long after treatment withdrawal (49, 50). 
Interestingly, treatment with the ViaR antagonist OPC 21268 alone has no effect on the 
full progression of the adult hypertensive phenotype while the V2 R antagonist OPC 31260 
actually exacerbates this progression (28, 43). In developing hypertension, again in the 
SHR, combination therapy with ACE inhibitor ramipril and OPC 21268 was not additive 
in its BP lowering effects (49). In an established hypertensive rat model, chronic treatment 
with OPC 21268 failed to lower BP (50) Thus far in the adult hypertensive model 
combination therapy with both ACE antagonism and ViaR blockade has not been 
investigated.
With regard to DM, regulation of the AVP system has thus far been little studied. The 
regulation of Via and V2 RS has been looked at in a 2  week, normotensive rat with 
streptozotocin-induced DM and this demonstrated an increase in plasma AVP with 
associated down-regulation of the ViaRs in both liver and kidney. The V2 R numbers 
remained unchanged (51). Little is known of AVP receptor regulation with more long 
term DM or in DM associated with hypertension.
The aims of this thesis therefore were: 1) to characterise in vitro a new range of non­
peptide, orally active, AVP receptor antagonists and further characterise in vitro and in 
vivo the most “promising” of the mixed antagonists in rat. 2) To look for any additive or 
synergistic benefits of ACE inhibition and ViaR antagonism in the adult hypertensive rat.
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3) To study the regulation of the AVP ViaR system in an 8  week, hypertensive, rat model 
of DM.
1.2 ARGININE VASOPRESSIN (AVP)
1.2.1 Structure and biosynthesis
1.2.1.1 Gene
The AVP gene, in humans, is assigned to chromosome 20 and contains 3 exons separated 
by 2 introns. The exons contain the genetic code for the functional domains of the large 
polypeptide precursor of AVP- preprovasopressin (52). Exon A encodes the actual 
hormone along with a 5’ untranslated region and the signal sequence. Exon B encodes 
most of the conserved part of the carrier neurophysin and exon C the remaining C-terminal 
variable neurophysin sequence, a glycopeptide and the 3’ untranslated region (52) (Figure 
1.1). The rat and human AVP precursor genes are highly conserved in structure and the 
three functional domains of the rat precursor -  AVP, neurophysin and glycoprotein- are 
encoded, as with the human precursor, on three distinct exons. The rat gene also includes a 
consensus sequence found at exon-intron junction. This is a modified RNA polymerase II 
binding site CATAAAT located 29bp upstream of the start point of transcription and a 
polyadenylation site in the 3’ untranslated region (52).
1.2.1.2 Protein
The post-translational processing of neuropeptide polyprotein precursors is an important 
feature of neuropeptide expression. The biosynthetic pathway for AVP, a 9 amino acid 
hormone, involves the proteolytic cleavage of its precursor preprovasopressin (53, 54). 
This precursor contains 3 peptide units- AVP and a signal peptide located at the N- 
terminus, the carrier neurophysin and a C-terminal glycopeptide. The hormone precursor
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undergoes a number of maturation steps with these processes occurring in the secretory 
vesicles during axonal transport. There are a number of consensus signals that are 
involved in modification and proteolytic processing. Separating AVP from the 
neurophysin are a pair of basic amino acids, that serve as a signal for proteolytic cleavage, 
and a glycine residue that is essential for the amidation of the AVP C-terminal amino acid 
(55). The neurophysin is connected to the C-terminal glycoprotein by a single basic 
residue. The glycopeptide contains a typical glycosylation site Asn-X-Thr although its 
physiological significance is unknown. Given that its sequence is highly conserved across 
species and that it is cleaved and secreted into the circulation along with AVP and 
neurophysin, it seems likely that the glycopeptide may confer some biological role (53, 
54). Post-translational modification begins with the transfer of the initial protein product 
from hypothalamic rough endoplasmic reticulum (rER) to Golgi apparatus and then further 
proteolytic maturation steps occur continuously during axonal transport with both cleaved 
and uncleaved products appearing in the posterior pituitary after a few hours (56). The 
Brattleboro (BB) rat represents an autosomally recessive form of nephrogenic diabetes 
insipidus (NDI) (57). These animals lack, not only circulating AVP, but also its 
corresponding neurophysin and the glycopeptide moiety. This disease state results from a 
frame shift mutation in the AVP gene that yields a mutated precursor protein unable to be 
transported to the Golgi apparatus for further processing (57).
Chapter 1: Literature review 10
AVP gene
5 ’ EXON A EXON B EXON C 3 ’
AVP mRNA TRANSCRIPTION
Poly A
AVP precursor protein: 
pr epr o vasopr essin TRANSLATION
NR, SP AVP NP i GP COOH
AVP
POST TRANSLATIONAL MODIFICATION 
Cys - Tyr - Phe - Gin - Asn - Cys - Pro - Aig - Gfy - NIL
s--------------------------- s
Figure 1.1. A representation of the structural organisation of the AVP gene, precursor and 
AVP peptide. Modified from (55)
Abbreviations: SP, signal peptide. NP, neuropeptide. GP, glycoprotein
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1.2.2 Storage and release
1.2.2.1 Central nervous system (CNS)
AVP is synthesised, transported within and secreted from two distinct classes of neurones 
found in the paraventricular (PVN) and supraoptic (SON) nuclei of the hypothalamus. 
Firstly, the magno-cellular AVP-containing neurones of the hypothalamic PVN and SON 
form the hypothalamic-hypophyseal pathway and this projects to the posterior pituitary 
where AVP is then stored and secreted into the general circulation (58). Secondly, the 
hypothalamic parvocellular neurones project to the median eminence where AVP and 
oxytocin are released into the portal vessel system to modulate anterior pituitary function 
(58). In addition, parvocellular AVP-containing neurones found within the hypothalamus 
have extrahypothalamic projections to centres in the medulla such as the nucleus tractus 
solitarius, the dorsal vagal complex, the locus coerulus and the intermedial column of the 
spinal cord, while axonal vasopressinergic projection to the forebrain and lateral septum 
may be involved in AVP’s role in memory and behaviour (58-60). There are also 
ascending catecholaminergic pathways from medullary centres that terminate in the PVN 
and SON. For example, noradrenergic axons from the ventral lateral medulla synapse with 
both magnocellular and parvocellular neurones of the PVN and SON. Those of the dorsal 
motor nucleus of the vagus and the locus coerulus, on the other hand, synapse 
predominantly on parvocellular neurones of the PVN (60-62). These ascending and 
descending pathways provide the basis for a possible feedback loop that enables AVP to 
influence autonomic and cardiovascular function as well as provide a structural basis for 
catecholaminergic effect on AVP release.
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1.2.2.2 Peripheral
Traditionally AVP was thought of as a neurohypophyseal hormone. Today, although AVP 
is predominantly thought to be synthesised within the hypothalamus, there is increasing 
evidence also for its production in peripheral tissues such as the aorta (35, 63), heart (36), 
coronary vasculature (36), platelets (64), ovary (32, 65), testis (6 6 , 67), pancreas (6 8 , 69), 
trachea (70), adrenal (71), thymus (72) and sympathetic ganglia (73, 74) of different 
species. The physiological significance of peripheral, locally produced AVP, is not clear 
although there is evidence to suggest that AVP may act locally to modulate hypertrophy 
and hyperplasia of cardiomyocytes (75) and smooth muscle cells as well as influence 
coronary vascular tone (36) and the actions of local growth factors such as transforming 
growth factor p (TGFp) (30, 31).
1.2.2.3 Osmotic control of release of AVP
In 1947 E.B.Vemey originally proposed the concept of osmoreceptors from studies that 
assessed the influence of body fluid hypertonicity on antidiuresis. He demonstrated that 
infusion of hypertonic and non sodium-containing solutions into the carotid arteries of 
dogs caused an antidiuresis. He also concluded that osmoreceptors influenced the release 
of an antidiuretic hormone from the posterior pituitary gland since intracarotid infusion of 
a posterior pituitary extract mimicked the antidiuresis observed when using hypertonic 
solution (17).
Lesion and electrophysiological studies have since provided strong evidence regarding the 
localisation of these osmoreceptors (76). Three anatomically defined areas of the lamina 
terminalis are implicated in water balance control. The organum vasculosum of the lamina 
terminalis (OVLT) and the subfornical organ (SFO) lie outside the blood brain barrier
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while the nucleus medianus (NM) lies within it. Where the SFO is primarily concerned 
with Ang Il-mediated thirst and AVP release, the OVLT is involved in osmotically 
stimulated AVP secretion (77). The NM acts to integrate signals from the SFO and OVLT 
and peripheral cardiovascular pathways and to provide stimulatory inputs to the 
magnocellular and lateral hypothalamic neurones for AVP release and thirst (78, 79).
1.2.2.4 Non-osmotic control of release of AVP
Non-osmotic factors such as hypovolaemia and hypotension can also stimulate AVP 
release from the posterior pituitary via two baroregulatory systems. Low-pressure volume 
mechanoreceptors found in the left atrium detect changes in blood volume. High-pressure 
volume mechanoreceptors located in the carotid sinus and aortic arch detect and respond to 
changes in BP (80). Consequently, increased BP and volume lead to increased firing of 
baroreceptors and decreased AVP release. In man, high pressure baroreceptors are thought 
to play a more important role than low pressure baroreceptors as only a 5% decrease in 
arterial pressure compared to a 10-15% reduction in blood volume is required to influence 
AVP release (80, 81).
Other factors known to affect AVP release from the hypothalamus include Ang II (82, 83), 
atrial natriuretic factor, satiety (84) and environmental factors (85, 8 6 ) such as temperature 
and humidity (87).
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1.3 AVP RECEPTORS
1.3.1 General overview
AVP mediates its physiological effects through G-protein-coupled membrane-bound 
receptors that have been divided into two broad subtypes based on their second messenger 
systems. (8 8 ). The classic antidiuretic effect of AVP is mediated through renal V2 R.S with 
cAMP production, via AC, as a second messenger while vasopressor action is mediated 
through VjRs, with phophatidylinositol phosphate hydrolysis as a second messenger. The 
anterior pituitary AVP receptor has been subclassified as a VibR on the basis of different 
profiles of [3H]AVP binding compared with classical hepatic/vascular ViaRs (89, 90). 
Since the molecular cloning of the VibR some have adopted the classification of V3 to 
describe this receptor and this is based on the fact that the VibR has no greater sequence 
homology with the ViaR as compared with other members of the AVP/oxytocin receptor 
family. As yet no international consensus has been reached regarding a new classification 
or nomenclature for this receptor and henceforth any reference to it within this thesis will 
use the Via, ViB and V2  classification.
1.3.2 Via receptors (ViaRs)
1.3.2.1 Molecular biology
In 1992, Morel et al first described the molecular cloning of a cDNA encoding rat ViAR 
isolated from rat liver, a particularly significant event in the history of AVP research (91). 
A number of groups have, since then, described the cloning, expression and distribution of 
rat, human and sheep ViaR genes (91-93). From these nucleotide sequences of this cloned 
cDNA the receptor protein amino acid sequences have been deduced.
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The translated ViaR protein is G-protein coupled and has the characteristic extracellular 
amino-terminus, an intracellular carboxyl-terminus and spans the cell membrane 7 times in 
between (Figure 1.2). This feature was deduced from their amino acid sequences by the 
relative positions and sizes of hydrophobic and hydrophilic clusters of amino acids. The 
amino acid sequence homology between human, rat and sheep ViaRs is approximately 70- 
80% (93). There is approximately 40% preservation of amino acid sequence between the 
rat AVP ViAR and the rat V2 R and almost half of the non-conserved amino acids are 
located in the extracellular amino-terminus and intra-cellular third loop. All receptors of 
the AVP/oxytocin subfamily have conservation of amino acids located in the first 2 
extracellular loops, a conservation that is not seen in other receptor subfamilies. The 
conserved sequence found in the first extracellular loop is FXGPDXLCRXVK while that 
in the second, DCWAXFXXPWG (94). It has been postulated that these shared amino 
acids, being unique, form part of a ligand recognition site (95). Moreover, it has been 
shown that a disulfide bond between cysteines (Cys124 and Cys205) in the first 2 
extracellular loops is essential to the integrity of the binding site (91). In a site-directed 
mutagenesis study the effects of single amino acid substitutions on AVP binding to the 
ViaR were examined in transfected COS-7 cells. Following a number of such 
substitutions, the conversion of Asp9 7  in the second transmembrane domain caused by far 
the greatest reduction in affinity for AVP (3800-fold decrease) and thus suggests that this 
particular amino acid has a key role to play in receptor recognition (96).
In terms of G-protein activation by the V iaR, an RTVK sequence at the distal membrane 
interface of the third intracellular loop is thought to play an important role here (96).
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The sequence NPWIY, found on the seventh transmembrane domain, is also conserved 
amongst the AVP/oxytocin family and is thought to be responsible for receptor-mediated 
endocytosis (77). The third cytoplasmic loop and the cytoplasmic tail contain a number of 
serine and threonine residues that are potential sites of regulation by protein 
phosphorylation while two adjacent cysteine residues in the cytoplasmic tail are potential 
sites for palmitoylation. This binding of fatty acid to amino acid serves the purpose of 
anchoring the cytoplasmic tail to the inner face of the plasma membrane (97).
1.3.2.2 Second messengers
Many biological signals are processed by the binding of chemicals to cell surface 
receptors. Signals are switched from these receptors to intracellular language via guanine 
nucleotide binding regulatory proteins (G-proteins) that are present in all eukaryotic cells 
and thus G-proteins serve as interfaces between receptor and biological responses. The 
ViaR is linked to a heterotrimeric G-protein (98). The stimulatory subunit (Gs) of this is 
activated following the binding of AVP and leads to activation of phospholipase C (PLC). 
This activated PLC causes hydrolysis of membrane lipid phophatidylinositol-4,5- 
bisphosphate to produce 2 second messengers: inositol 1,4,5-triphosphate (IP3 ) and
diacylglycerol (DAG). IP3 acts on intracellular IP3 receptors located on the smooth 
endoplasmic reticulum (sER). These receptors form a calcium selective ion channel and, 
following binding of IP3 , this IP3 receptor ion channel opens to release intracellular stores 
of calcium from the sER into the cytosol. DAG formed from activated PLC activates 
protein kinase C (PKC) (19, 20, 99)(Figure 1.2). Stimulation of ViaRs in smooth muscle 
cells or Chinese hamster ovary cells has been shown to stimulate other signal transduction 
pathways involving phospholipase A2 , C and D (100, 101). Activated ViaRs have also 
been shown to stimulate tyrosine phosphorylation in fibroblast-like Swiss 3T3 cells (102).
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Activated V iaRs have been shown to induce protein synthesis in neonatal cardiomyocytes 
via increased stimulation of the mitogen-activated protein kinase signal transduction 
pathway and intracellular calcium (75, 103).
1.3.2.3 Localisation and distribution
In vitro autoradiographic techniques have demonstrated that the ViaR is widely distributed 
throughout the body.
In the rat brain ViaRs have been found in many regions such as the lateral septum, bed 
nucleus of the stria terminalis, arcuate nucleus, area postrema, choroid plexus as well as 
within the blood vessels (104-108). In situ hybridisation histochemistry (ISHH) studies 
have subsequently confirmed and extended the above distribution for the ViaR by 
demonstrating ViaR mRNA transcripts throughout the brain (109, 110).
In the heart, V iaRs have been shown to be associated with the cardiomyocytes (111-113) 
and with the coronary vasculature (36, 114).
In the kidney, V iaRs are found in the outer part of the inner medulla associated with the 
vascular structures, in the inner stripe of the outer medulla associated with the vasa recta 
(42, 106) and within nephron segments (115). Although localisation studies have failed to 
show V iaR mRNA in glomeruli of normal adult rats, ViaR mRNA is present in glomerular 
mesangial cells in developing rat kidney (116). V iaRs are known to be present on the 
luminal membrane of the collecting tubule principle cells (117-119).
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In liver, V iaR protein and mRNA is associated with the hepatocytes and vascular epithelial 
cells, as well as with human hepatic stellate cells (106, 109, 120-125).
ViaRs have also been localised to vascular smooth muscle cells, gonads and sympathetic 
ganglia (106), platelets (126, 127), peripheral mononuclear cells (128), thymus, spleen 
(129), adrenal (130,131), uterus (132), as well as lung (133).
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Figure 1.2. A representation of the ViAR system and its interaction with second 
messengers.
Abbreviations: P 04, phosphate. Ca2+, calcium. GDP, guanidine diphosphate. GTP, 
guanidine triphosphate.
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The expression of mRNA for ViaRs is developmentally regulated and tissue specific. For 
instance, by reverse transcriptase polymerase chain reaction (RT-PCR), ViaR mRNA was 
detected in newborn rat heart but not in the adult rat heart (134). By contrast, ViaR 
mRNA was detected in adult lung but not in that of the newborn while the expression in 
liver from newborn rats compared to that in the adult has been shown to be lower (134). In 
embryonic (day 16-19) kidney tissue, ViaR mRNA predominates in the developing cortex 
but by 1 day old this has switched to the vascular elements, cells in the developing 
medullary collecting ducts (CD) and mesangial cells of glomeruli (110).
1.3.2.4 Biological actions of AVP at the V iaR
The principle physiological effects and sites of action for AVP are summarized in figure 
1.3.
Renal effects: Although blood flow to the inner renal medulla comprises less than 1% of 
the total renal blood flow, changes in flow to this region can have a major effect on sodium 
and water homeostasis and on the long-term control of arterial BP (135). Using 
videomicroscopy and laser-Doppler flowmetry techniques it has been shown that AVP has 
unique effects to modulate renal urinary concentrating ability through its vasoconstrictor 
effects on the medullary microcirculation to decrease renal medullary blood flow in 
anaesthetised rats (135-137). Infusion of.a ViaR selective agonist [Phe2 ,Ile3 ,Om8]AVP 
into the renal medulla selectively reduced blood flow in the outer medulla by 15% and to 
the inner medulla by 35% and resulted in a sustained hypertension. This suggests that the 
observed increase in BP may be related to changes in medullary blood flow (138-140). 
Stimulation of V2RS by medullary interstitial infusion of the V2R agonist l-desamino-8 -D- 
AVP or infusion of AVP in rats, pretreated with a ViaR antagonist, increased medullary
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blood flow by 16% and 27% respectively (141, 142). These studies suggest that, in terms 
of renal medullary blood flow, AVP has 2 opposing actions resulting from stimulation of 
Via and V2R.S. It seems likely therefore, that as a result of this balance, AVP itself is 
unable to induce systemic hypertension or sodium retention (142).
The role of AVP to modulate glomerular function is unclear. Although glomerular 
mesangial cell ViaRs have been described in vitro (143) their presence in vivo, in adult rat, 
has not been clearly identified. In vitro studies have suggested that AVP may modulate 
growth of glomerular mesangial cells in a similar way to vascular smooth muscle cells 
(144, 145). In the SHR, infusion of low and high dose AVP, at subpressor levels, for 15 
days, led to dose-dependent proliferative changes that were associated with increased 
expression of TGFpi and collagen type-1. This suggests that AVP may contribute to 
glomerular proliferation and that AVP may exert its effects, in part, via induction of TGF- 
p l (31). Chronic and selective blockade of the ViAR with OPC 21268 did not lower BP in 
salt-loaded SHR but did lead to a suppression of glomerular platelet derived growth factor 
B-chain and proliferative cell nuclear antigen (30). Taken together, data from these studies 
suggest that AVP, via the ViAR, may play a role in modulating glomerular function 
particularly in hypertensive states where renal proliferative injury is not uncommon.
Cardiac effects: There is increasing evidence to suggest that the heart is a target organ for 
AVP. In vitro studies show that AVP mediates negative inotropic effects in the dog heart 
(146) and modulates nitric oxide synthase activity in cardiac myocytes (147). Recently 
cardiac AVP mRNA has been detected in isolated, perfused, pressure overloaded rat hearts 
and localised mainly to endothelial cells and vascular smooth muscle cells of arterioles and 
perivascular tissue (36). The induction of cardiac AVP in this pressure overload model
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subsequently led to coronary vasoconstriction and impaired relaxation and these effects 
were prevented by ViaR blockade (36). A study in the isolated perfused rat heart in which 
coronary artery blood flow is kept constant has shown that AVP, via activation of 
cardiomyocyte V iaRs, produces a positive inotropic effect at low concentrations and a 
negative inotropic effect at higher concentrations (148). It has been suggested that AVP 
may play a role in the regulation of cardiomyocyte contractility via activation of the VJAR 
and a subsequent increase in intracellular calcium (149). In the rabbit heart, AVP has been 
shown to induce protein synthesis and this is mediated via the calcium dependent V iaR 
(150).
Central effects: Although AVP is one of the most potent vasoconstrictors of vascular 
smooth muscle known, supra-physiological concentrations of AVP are required to cause 
any BP increase (151). This is secondary to a central effect of AVP that enhances those 
cardiovascular reflexes that buffer any such BP rise. Studies examining the effect of AVP 
on arterial baroreflex function have shown that constant infusion of AVP results in a dose- 
dependent reduction in heart rate and sympathetic nerve activity in response to an increase 
in arterial pressure and that this ultimately leads to a leftward shift of the baroreflex curve 
(152, 153). Furthermore, several lines of evidence point to the ViAR as that responsible for 
these AVP effects on baroreflex action. In the rabbit (154) and baboon (155), 
administration of a VJAR antagonist blocks the effect of AVP on baroreflex function. The 
effect of AVP infusion and that of selective Vi and V2 R antagonists and agonists on 
baroreflex control of heart rate, during changes in arterial pressure, has also been evaluated 
in conscious rabbits (153). These authors found that a selective VjR antagonist blocked 
the characteristic shift in baroreflex function to lower pressures caused by AVP. 
Furthermore they were able to mimic the action of AVP in this regard using a selective
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ViR agonist, while a selective V2 R agonist had no effect. These central effects of 
circulating AVP on the baroreflexes appear to be mediated primarily through the area 
postrema. This region has a number of projections to centres in the brain involved in 
cardiovascular regulation such as the NTS. The NTS is rich in AVP V iARs and is devoid 
of a blood-brain barrier and thus is ideally suited to respond to and modulate the 
cardiovascular actions of circulating hormones. For instance, microinjections of small 
amounts of AVP given directly onto the area postrema caused a dose-dependent decrease 
in renal sympathetic nerve activity and enhanced baroreflex sympatho-inhibition during 
infusions of adrenaline (156).
Hepatic effects: In rodent liver, AVP acts through hepatic ViaRs to stimulate
glycogenolysis, gluconeogenesis and raise blood glucose (157-159), effects that have been 
demonstrated in other animals (159) and also in man (158). AVP has also been shown to 
stimulate urea synthesis within the liver and this is thought to contribute to providing more 
urea to the kidney for improving urinary concentrating capacity (160). Although not tested 
in vivo AVP, through ViAR-mediated contraction and proliferation of human hepatic 
stellate cells, may also play a role in modulating sinusoidal resistance (161).
Platelet effects: Other AVP actions mediated through the ViAR include the promotion of 
platelet adhesion, aggregation and secretory activity (162, 163). In humans,
immunoreactive plasma AVP concentrations have been shown to be higher in platelet rich 
plasma compared to platelet poor plasma in normal individuals, as well as those with 
hypertension and CCF (164, 165). The physiological significance of this platelet AVP is, 
at present, not clear. It has been proposed however that the platelet may act as a carrier of 
AVP, presumably via binding to its V iAR. As platelets are in close apposition to the
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vascular wall they may provide a mechanism for delivery of a higher concentration of 
AVP to local vascular sites (64).
Adrenal effects: ViaRs have been found in the zona glomerulosa and fasciculata of the 
human adrenal gland (166). AVP, through its effects at the ViaR, is as potent as Ang II in 
stimulating the release of aldosterone from glomerulosa cells in vitro and stimulates 
cortisol release from fasciculata cells (166).
Mitogenic effects: AVP, via activation of the ViaR subtype, is increasingly recognised as a 
cellular growth factor and this effect has been implicated in a number of normal and 
pathophysiological responses (167, 168). In vascular smooth muscle cells, AVP induces 
hyperplasia and hypertrophy (169) as well as stimulating the expression of early growth 
response genes (170, 171).
Uterine effects: In both rats and humans, the myometrium is sensitive to AVP and
oxytocin. In rats, the myometrium is more responsive to oxytocin yet the binding affinities 
of the 2 peptides to myometrial receptors are roughly identical (172). However in the 
human uterus the non-pregnant myometrium responds more strongly to AVP, a situation 
that is reversed as term approaches (173). It is unclear at this stage through which receptor 
type oxytocin and AVP are acting as [H]oxytocin can displace both AVP and oxytocin 
from uterine membranes (174, 175). A study using OPC 21268 suggests that the V iaR is 
responsible as this selective V iaR antagonist inhibited both oxytocin- and AVP-induced 
contractions of myometrial strips from rats and full-term pregnant women and did so in a 
dose-dependent and reversible manner (172).
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Eye effects’. Little is known of the AVP system within the eye and information currently 
available in the literature is often conflicting. AVP has been demonstrated within the 
mammalian retina, anterior uvea and iris (176-179) and at physiological levels can 
stimulate active sodium transport into the eye to raise intraocular pressure (IOP) (176). 
This would suggest that AVP receptor blockade represents a good target in the treatment of 
diseases associated with raised IOP such as glaucoma and diabetic retinopathy. In cultured 
human retinal pigment epithelial cells AVP has been shown to stimulate the production of 
IP3 and calcium and this effect is inhibited by prior treatment with a ViaR blocker (180). 
In the same model, another group, while demonstrating an increase in the IP3 second 
messenger system, found this to be activated by the addition of a V2 R agonist with only 
limited activation with a ViR agonist (181). In the monkey, a tritiated ViR antagonist was 
found to bind with high density in the region of the iris (182). Recently a study using a 
rabbit model with raised IOP demonstrated lowered pressures after treatment with the V2R 
selective antagonist SR 121463 and this drug had a good local and systemic safety profile 
within this model (183).
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Figure 1.3. A representation of the biological actions of AVP at the V iaR.
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1.3.3 V2 receptor (V2R)
1.3.3.1 Molecular biology
Molecular cloning of the X chromosome and deduction of the amino acid sequence for the 
human and rat V2R was accomplished in 1992 (184, 185) along with the genomic 
organization of the human V2 R gene (186). In addition the rat V2R promoter region has 
also been sequenced by inverse PCR mediated cloning (187). The translated V2R protein 
has the characteristics of a G-protein coupled, 7 transmembrane domain, receptor 
consisting of 7 hydrophobic regions connected by 3 extracellular and 3 intracellular loops. 
The molecular weights of the rat and human V2RS are similar (40,518 d compared with 
40,285 d respectively) and the human V2R displays approximately 8 6 % sequence 
homology with the rat V2 R (187). The coding region of the rat and human V2R genes is 
interrupted by 2 short introns. In rat kidney there are 2 mRNA variants, V2L and V2 S,
shown to arise from a single V2R gene by alternative gene splicing (188). The long (V2O
form encodes the AC-coupled receptor. The short (V2 s) form of the receptor lacks the 
nucleotide sequence encoding the putative seventh transmembrane domain and is inactive 
on the AC pathway within transfected cells (188). Quantitative RT-PCR on micro­
dissected nephrons demonstrated that neither V2L nor V2 S are expressed in glomeruli and 
proximal tubules, whereas they are present in the ascending limb of the Loop of Henle and 
the CD (188). In all nephron segments the ratio of V2 S to V2 L mRNA is constant at 15% 
and therefore high V2 S levels are only observed within the CD (188). The V2R has a single 
site for N-glycosylation at asparagine 22 located at the extracellular N-terminus (189). 
Likewise, utilising such techniques as site-directed mutagenesis and sialidase treatment of 
the receptor protein, it has been shown that O-glycosylation is present on most of the 
serines and threonines at the amino terminal end (190). From transfection experiments, the 
functional significance of these post-translational modifications remains unclear as mutant
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V2R.S, that lack the target amino acids for N- and O-glycosylation, function in a manner 
indistinguishable from the wild type receptor (190).
NDI is a rare clinical condition resulting from mutations in the V2R and aquaporin-2 genes 
(AQP-2). It is characterised by an inability of AVP to concentrate urine and therefore 
regulate water homeostasis and this in turn leads to polyuria, severe dehydration and in 
severe cases, even death (191). It has 2 types of inheritance, X-linked and autosomal 
recessive. More than 130 mutations in the V2R gene (the X linked type) have been 
described for this disease and these account for 95% of cases. Genetic linkage studies 
have localised the NDI locus to the q28-qtr region of the X chromosome (192, 193). The 
other 5% (autosomal recessive type) of patients have normal V2RS but have mutations that 
disrupt the gene encoding for AQP-2 (194-198). The majority of these are single amino 
acid mutations that result in protein configurational changes and the trapping of the 
abnormal proteins within the sER (199). The number of receptors present on the cell 
surface are thus reduced or abolished. Other mutations still allow the receptor to be 
present on the cell surface but may alter the ligand-receptor binding affinity or reduce the 
coupling efficiency to Gs (199-202). One of the first characterised mutations of the V2R, 
associated with NDI, is a substitution of arginine 137, found at the cytoplasmic end of 
transmembrane domain III, for histidine (R137H). The functional consequence of this 
mutation has been shown to be a constitutive arrestin-mediated desensitisation in that, 
unlike the wild-type V2R, the non-signalling R137H receptor is phosphorylated and 
sequestered in arrestin-associated intracellular vesicles even in the absence of agonist 
(203). Current treatment strategies for NDI include the limitation of fluid and dietary 
sodium intake as well as thiazide and amiloride administration (199). In most cases these 
control the disease but are non-curative. Current research into curative treatments is
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focusing primarily on gene therapy (204) but also on chemical chaperones that restore the 
routing of AQP-2 mutants to the apical membrane of the CD (195). Once in situ these 
receptors retain the ability to function as normal (205).
1.3.3.2 Second messengers
The activation of the V2R by AVP serves to increase water reabsorption from the urine into 
the bloodstream and this is effected as follows. Activated V2R.S stimulate AC via the 
stimulatory G-protein Gs. This results in an increase in the second messenger cAMP that 
activates protein kinase A (PKA) and starts a phosphorylation cascade leading to the 
insertion of the AVP sensitive water channel AQP-2 into the apical cell membrane (21, 22, 
206-210). To date, the mechanism by which an increased cAMP stimulates the 
microtubular-dependent reversible translocation of AQP-2 from cytoplasmic vesicles to 
apical cell membrane has not been clarified. Figure 1.4.
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Figure 1.4: A representation of the V2 R and its interaction with second messengers to 
effect its principal action of enhancing water retention in the kidney. WCV=Water 
carrying vesicle, also known as AQP-2.
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1.3.3.3 Localisation and distribution
In contrast to the wide distribution of the V i a  and V jb R s ,  functional V2 R protein has only 
been demonstrated in the principle cells of the CDs and inner medullary CD cells of the 
kidney (210, 211). More specifically the V2R protein has been localised to the basilateral 
component of cells of the cortical and medullary CDs as well as cortical and medullary 
thin ascending limb and distal convoluted tubule.
In rat, using ISHH, V2 R transcripts have been detected in high amounts in the renal inner 
and outer medulla, primarily associated with CDs. Sparser labelling has been found in the 
renal cortex with no “grains” being seen in the glomeruli (109). Further studies by the 
same group, again using ISHH, demonstrated the presence of V2R mRNA in rat at 16 and 
19 days gestational age with labelling being localised to the cells of developing medullary 
and cortical CDs. After birth the V2 R mRNA is located in cells of differentiating thick 
limbs of the loops of Henle, papillary surface epithelium, overlying macula densa, and 
short distal nephron segments (109). In contrast to kidney, liver did not express V2R 
mRNA at any time (116, 134). In the brain V2R mRNA was found to be present in the 
newborn rat but this expression decreased with time such that none could be detected in 
rats older than 2 weeks of age (134). Others have found V2R mRNA in the hippocampus 
of the adult rat brain, an area associated with memory and learning (212). Using RT-PCR, 
DNA sequencing and Northern blot analysis; V2R mRNA has been identified in the human 
lung (213).
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1.3.3.4 Biological actions
Renal: The principle action of the V2R is to modulate salt and water homeostasis via the 
retention of water through the CDs of the kidney. Regulation of water permeability by 
AVP has been shown in the cortical CD (214), the outer medullary CD (215, 216), the 
initial intramedullary collecting duct (IMCD)(217), and the terminal IMCD (218, 219). In 
contrast, urea permeability is regulated via AVP, but only in the final segment of the CD 
and the terminal IMCD (217). The predominant action of AVP in the CD, via the V2R, is 
to increase the permeability of the apical membrane and this is achieved by the insertion of 
the water channel AQP-2 into that membrane (Figure 1.4).
AVP acting at the renal V2R, at concentrations seen following dehydration or low dose 
infusion, produces significant renal vasodilatation in conscious dogs without significant 
change in mean arterial pressure, cardiac output or heart rate (220). The mechanism for 
this particular AVP effect remains unclear at this stage. It may involve blockade of 
vascular V2  or V2 -like receptors or be mediated through an AVP reduction in renal 
sympathetic tone effected from the area postrema (2 2 1 ), as central facilitation of the 
arterial baroreflex to AVP has been shown to be mediated by a V2 -like receptor (222, 223).
Other biological actions: The existence of non renal actions for AVP have been proposed 
indirectly based on observations from a number of physiological studies. For instance, in 
humans, AVP has been shown to stimulate forearm dilatation and that this is caused by 
V2R mediated endothelial derived relaxing factor or nitric oxide release from vascular 
endothelial cells (224, 225). Additionally, the AVP V2R agonist l-deamino-8 -D-AVP 
(dDAVP) induces von Willebrand factor release from endothelial cells, megakaryocytes 
and peripheral blood monocytes (226, 227). This response is reduced in patients with NDI
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which further supports the role of AVP in these findings (198). AVP also stimulates 
cAMP accumulation in human mononuclear cells (228).
Antidiuresis Vasodilatation
Von Willebrand factor release
Figure 1.5. A representation of the biological actions of AVP at the V2R.
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1.3.4 Vib receptor (VibR)
1.3.4.1 Molecular biology
Molecular cloning and deduction of the amino acid sequence for the human VibR was 
accomplished in 1994 (229, 230) closely followed by the rat VibR (231). The translated 
VibR protein, as with the Via and V2R, is a G-protein linked receptor with the classical 7 
transmembrane domains consisting of 7 hydrophobic regions connected by 3 extracellular 
and 3 intracellular loops. The molecular weights of the rat and human VibRs are similar 
(47,03 Id and 46,977d respectively) with the rat and human ViBRs having approximately 
81% sequence homology (229, 230). The genomic organization of the ViBR closely 
resembles that of the V2 R with the intron at the same location between the first and second 
transmembrane domains in their coding regions (186, 188, 231). The N-terminal region 
preceding the first transmembrane domain contains a single glycosylation site at Asn21
(229). In humans the residues Lys-Val-Lys (231-233) and Lys-Ile-Arg (271-278), in the 
third intracellular loop, are conserved both in the Via and ViBRs but not in the V2R and 
may be important for the coupling of receptor and the PLC second messenger system
(230).
1.3.4.2 Second messengers
A VP activation of the VibR, in a manner analogous to the ViAR, results in activation of G- 
proteins and this in turn switches on PLC. PLC then catalyses the hydrolysis of 
phosphatidylinositol (4,5) bisphosphate and regulates target cell action via firstly, the 
generation of IP3 and mobilisation of intracellular calcium and secondly, PKC activation 
via the generation of DAG (19, 20, 99, 232).
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1.3.4.3 Localisation and distribution
The classical location of the VibR is in anterior pituitary corticotrophs (233). Until very 
recently no specific antagonists have been available for this receptor and study of the VibR 
has thus far proven very difficult. With the technique of immunohistochemistry, the VibR 
protein has found to be widely spread throughout the brain, for instance, in the 
hypothalamus, amygdala, cerebellum, hippocampus and particularly in those areas with a 
“leaky” blood brain barrier or close to the circumventricular organs such as the medial 
habenula, SFO, organum vasculosum laminae terminalis and the median eminence (234). 
VibR protein has also been described in rat and human adrenal medulla and in 
pheochromocytoma (130, 231, 235). VjbR mRNA transcripts have also been detected 
outside the brain in thymus, heart, lung, spleen, kidney, uterus, breast (231, 236, 237) and 
adrenal medulla (131). In March 2002, a novel non-peptide selective VibR antagonist 
became available and has been characterised both in vivo and in vitro (47). This should 
further open the way to understanding the diverse functions of AVP as it acts through the 
VibR.
1.3.4.4 Biological actions
AVP classically acts through the pituitary V ibR to work in synergism with corticotropin- 
releasing factor in the regulation of the release of adrenocorticotropin hormone (ACTH) in 
response to stress (104, 238-240). In the adrenal medulla, V ibRs within the chromaffin 
cells, regulate the release of catecholamine and are also involved in the secretion of 
ACTH. The widespread distribution of the VibR within the brain would suggest that some 
of the central actions of AVP such as learning, memory and neuroendocrine activation, 
previously attributed to the V iaR, may be resultant upon VjbR activation instead. In 
support of this V ibR knockout mice demonstrated behavioural changes (241).
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1.4 NON-PEPTIDE AVP RECEPTOR ANTAGONISTS
Little more that 10 years ago it was extremely difficult to determine the role of AVP in 
CVDs because of a lack of suitable receptor antagonists. Whilst peptide AVP antagonists 
have been available for a long number of years now, their short half life, duration of action 
and parenteral administration has prevented their use in long-term study or their clinical 
development. Indeed much of the controversy that still surrounds the importance and 
function of AVP relates to the acute nature of previous studies using these peptide blockers 
as it is well recognised that initial responses to the blockade of homeostatic systems do not 
necessarily predict the more relevant long-term effects (50, 242). In addition, marked 
species heterogeneity exists for the peptide V2 R antagonists in vivo and this further 
complicated their clinical development as aquaretic agents (243). The development of 
non-peptidic, orally active, AVP receptor antagonists has made it possible to further 
investigate the role of AVP within disease since, for the first time, it is possible to block 
AVP receptors chronically and assess the functional consequences of this. Some of these 
non-peptide receptor antagonists have been researched extensively while others are 
currently under investigation (Table 1.1). Potential therapeutic indications for AVP 
receptor antagonists comprise:
1. The blockade of the V iaR in arterial hypertension, CCF, Raynaud’s syndrome, 
peripheral vascular disease and dysmenorrhoea.
2. The blockade of the V2 R in the SIADH, CCF, liver cirrhosis, nephrotic syndrome and 
any state of excessive retention of free water and subsequent dilutional hyponatraemia.
3. The blockade of V 1 bRs in ACTH-secreting tumours.
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Table 1.1: Summary of some of the non-peptide AVP receptor antagonists currently under 
clinical development.
Adapted from (42, 244, 245). Ki, or inhibition constant, is the concentration of antagonist 
required to inhibit 50% of the maximal Via or V2 R effects of AVP.
p 1 s > I= ° 1
■d
1 1
«rM V•9 g•d £ •  «n» s
I t
M JH■sf*d«S
1!
■d
£
■d
1 1
I
1 IC^-0^0
•d
1 1
•9•d 5 
« *oa s
| t
m y,■§§ •d £ «*d
*1(2-&
i
-  a
Jj
£
■d
1 1
h 1
IA00+0
i
0
«*
t  t■s |  » s
i t
«
■Sf*d ,2 «*d
| t
1
*•d *>
IT
£
■d
1 1
OPC
 4
106
1
1 Iro
I
c«
H
M t
•§ t•d ,8 V d3 S
i t
« _m y
s*d ,§
i t
1
*d ^|-i§ £
•d
1 1
W
S
P*
«
M
1 Ic<
H
I
-s.H
1 §•d ,S« d3 6
i t
m y
s*d JSV 2
I t
•d
£
■d
1 1
O
cm
n
U
fr
O
1
**HCl
I
vin
4f
•3 f•d .S« *d» s
I t
I t*d £
i t
•d
£
•d 
» 1
ft ■d ■d *d •d
1M 1 H e> 1 1 1 1 1 ] £ t 1
Ufa
O
1 I
H
§ f i A l a
•d
1 1
•d
1 1
■d
1 1 £ vtS
!
2 S
h
Is
rfl
1*
| 4
l l i t
8
gj> & 3
Chapter 1: Literature review 38
1.4.1 OPC 21268: ViaR antagonist
1 -(1 - [4-(3 -acetylaminopropoxy)benzoyl] -4-piperidyl} -3,4-dihydro-2( 1 H)-quinolinone or
OPC 21268 has selective effects at the ViaR and in 1991 was the first non-peptide AVP 
receptor antagonist to be described (244). It was developed by optimisation of a lead 
structure that was found by the screening of several thousand compounds (244). The drug 
was further characterised in vitro and in vivo in the rat (123) and since that time has been 
used widely and added a great deal to our understanding of the actions of the ViaR in 
disease. In rat, for instance, it has been shown to lower BP both acutely and chronically in 
mineralocorticoid hypertension (28) and to reduce BP in young SHR (50). The 
administration of OPC 21268 to rats with cold-induced brain injury and oedema exerted a 
significant protective effect, particularly in the areas where the maximum amount of blood- 
brain barrier breakdown was seen (246). OPC 21268, given to a rat model of diabetic 
nephropathy, significantly reduced albuminuria (247) and, again in rat, OPC 21268 also 
reduced the incidence of alcohol-induced gastritis (248).
After rapid ventricular pacing in the dog, a model of decompensated CCF, OPC 21268 
significantly increased cardiac output and reduced total peripheral resistance and mean 
arterial BP (37). Unfortunately, there is great species variability in the response to OPC 
21268 and its affinity for human V iaRs is rather weak (249, 250). For instance OPC 
21268 failed to prevent the AVP-induced contraction of human internal mammary arteries 
harvested from patients undergoing coronary artery bypass surgery (249). This has 
therefore greatly limited its clinical development. A recent study has demonstrated that the 
second transmembrane domain of the V iaR and in particular the amino acid residue Ala- 
342, which is absent in the human receptor, is responsible for the high affinity binding seen 
in the rat (251). This drug will be used alone and in combination with an ACE inhibitor in
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a bid to look for additive benefits of dual therapy within a rat model of established 
hypertension in chapter 4 of this thesis.
1.4.2 SR 49059: ViaR antagonist
(^SH-t^RSS^-S-chloro-S-^-chloro-phenyO-l-O^-dimethyoxybenzene-sulfonyl)^- 
hydroxy-2,3-dihydro-l//-indole-2-carbonyl]-pyrrolidine-2-carboxamide) or SR 49059 was 
developed and characterised in 1993 (42). It has a marked affinity and selectivity for the 
ViaR, no partial agonist activity and no significant effects at the V2R (42, 252, 253). 
When studied in the Swiss 3T3 fibroblast model SR 49059 was shown to exhibit the most 
potent antiproliferative effect of any ViAR antagonist yet seen (254). Its main advantage 
over OPC 21268 is its effectiveness, not only at animal, but also human ViaRs and thus is 
likely to prove a useful tool for studying the pathophysiological role of AVP in man and 
has greater potential for clinical development (255). In phase one trials it proved not only 
to be highly effective in reducing the ViaR dependent end-points of platelet aggregation 
and skin blanching but had an excellent side effect and safety profile also (256).
1.4.3 OPC 31260: V2R antagonist
In 1992, through modification of the structure of OPC 21268, Yamamura et al developed 
and characterised a potent V2R, non-peptide antagonist and named it (5-dimethylamino-l- 
[4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro- l//-benzazepine hydrochloride) or 
OPC 31260 (43). It is a competitive AVP receptor antagonist with a renal V2R: hepatic 
ViaR selectivity ratio of 25:1 (28, 123). Interestingly, OPC 31268 was the first non­
peptide, AVP V2R blocker effective in humans to increase free water clearance. Its mode 
of diuretic action, being different from that of previously known diuretic agents such as
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frusemide and bendrofluazide, is characterized as an aquaresis. After the administration of 
a traditional diuretic agent water loss accompanies sodium excretion. With V2R 
antagonism sodium is conserved while water alone is passed (43). With the discovery of 
OPC 31260, therefore, came the huge potential for the clinical development of drugs to 
combat the various medical conditions associated with water retention and hyponatraemia 
such as SIADH, CCF, liver cirrhosis and the nephrotic syndrome. Various animal and 
human studies have been undertaken using this drug and a number of these are outlined 
here. In dogs, the renal vasodilatory response resultant from exogenous AVP 
administration was blocked by OPC 31260 without any concomitant changes in cardiac 
output (220). OPC 31260 was found to be as effective as water restriction in the treatment 
of SIADH (257). Similar studies have shown good treatment efficacy in humans and rat 
although interestingly, lower doses were required to produce similar aquaretic responses in 
these species (257). In the male rat, pre-treatment with OPC 31260 significantly increased 
the vasopressor response to exogenously administered AVP, providing evidence for a V2 - 
like receptor related vasodilator effect in these animals (258). Short-term antagonism of 
the V2R during the BP development phase in the SHR results in a paradoxical increase in 
BP that persists following treatment withdrawal, and suggests a role of the V2 R in 
preventing the development of hypertension in this animal model (49). In a 4 week study 
using a rat model of compensated CCF, chronic treatment with OPC 31260 resulted in a 
sustained and significant aquaresis but no survival benefits. Likewise no positive 
influences on cardiac remodelling or function were seen and plasma AVP levels were 
significantly elevated with this treatment (41). In human studies this drug has been shown 
to have beneficial aquaretic effects in SIADH, liver cirrhosis and in the prevention of 
cerebral oedema after subarachnoid haemorrhage (38, 259, 260).
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1.4.4 YM087: V1A/V2R antagonist
(methyl-1,4,5,6-tetrahydroimadazo[4,5-d] [ 1 ]benzoazepine-6-carbonyl]-2- 
phenylbenzanilide monohydrochloride), more simply known as YM087 or conivaptan, is a 
newly discovered non-peptide AVP receptor antagonist that has an affinity for both rat Via 
and V2RS that is equipotent to that seen with AVP itself (46, 169). It is a competitive 
antagonist at both the ViA and V2RS with no agonist properties and is the first mixed AVP 
receptor blocker to be described (46). YM087 has been shown to be an effective dual 
blocker in both animal (rat and dog) and human models (169, 261-264). In cultured rat 
neonatal cardiomyocytes, YM087 has been shown to prevent the AVP-induced increase in 
protein synthesis within this system and may therefore potentially be of clinical benefit in 
any diseases that involve cardiomyocyte hypertrophy (103). Likewise, in cultured rat 
vascular smooth muscle cells, YM087 potently and concentration-dependently inhibited 
AVP-induced hyperplasia and hypertrophy (169). In dogs with pacing-induced CCF, IV 
administration of YM087 not only promoted a marked water diuresis but also significantly 
increased cardiac output and significantly decreased left ventricular end-diastolic pressure 
and total peripheral resistance (265). In human studies, YM087 has been shown to be a 
highly effective treatment when given long-term to patients with SIADH who are 
refractory to water restriction. A more recent study has shown that a single IV dose of 
YM087, given to patients with advanced CCF (New York Heart Association class III and 
IV), resulted in a dose-dependent increase in urine output and also a significant reduction 
in pulmonary capillary wedge pressure and right atrial pressure when compared to placebo 
(266). These studies suggest that this drug may find clinical use as treatment for diseases 
associated with hyponatraemia and in particular CCF.
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1.5 AVP IN PATHOPHYSIOLOGICAL STATES
AVP, its effects in CVD, as well as the regulation of its receptor system has received 
relatively little attention thus far and the precise role it has to play in conditions such as 
hypertension and DM remains controversial (41, 50, 242). Since the advent of the non­
peptide receptor antagonists and selective radioligands, research has demonstrated the 
likelihood that AVP is important in these CVDs. Specifically relevant to this thesis is the 
role of AVP in hypertension and DM.
1.5.1 Hypertension
Given that AVP is a vasoactive peptide having vasoconstrictor effects through ViaRs in 
vascular smooth muscle and the brain and an antidiuretic action through activation of V2 RS 
in the renal tubule, it seems likely that this hormone will have a role to play in the 
development and/or maintenance of hypertension. To date, however, surprisingly little is 
known regarding the precise role that this hormone has to play in the pathophysiology of 
this condition.
1.5.1.1 AVP and hypertension: evidence from animal models
Initially the discovery that SHR cross-bred with the BB rat still developed hypertension 
was a strong argument against the importance of AVP in genetic hypertension, but the 
subsequent finding of AVP-like immunoreactivity, indistinguishable from authentic AVP, 
in peripheral tissues of the BB rat casts doubt on the validity of this argument (35, 49, 50, 
63). The development of non-peptide, orally active and selective AVP receptor 
antagonists have allowed reassessment of the role of AVP in both the development and 
maintenance of high BP but it remains controversial. Studies using the V iaR antagonist,
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OPC 21268, confirmed the importance of AVP in the maintenance of BP in volume 
expanded states such as mineralocorticoid hypertension where AVP levels are elevated 
(28) and demonstrated conclusively that AVP is not involved in the maintenance of BP in 
either renovasular (267), genetic hypertension (50) or more recently ACTH-induced 
hypertension (268). However the importance of AVP in the development of hypertension 
has been demonstrated in the SHR in a manner analogous to ang II (49, 50). This study 
also demonstrated a lack of additive BP lowering benefits of ViaR antagonism and ACE 
inhibition and interestingly that the use of V2 R selective antagonist OPC 31260, again 
during the developmental phases of hypertension, actually augmented hypertension in 
adult SHR. No study, as yet, has looked for any additive BP lowering effects of ACE 
inhibition and ViAR antagonism in the adult SHR with established hypertension, part of the 
remit of this thesis.
1.5.1.2 AVP and hypertension: evidence from human studies
The contribution of AVP to the maintenance and development of human hypertension is 
not well understood at this time. Results regarding plasma AVP levels in hypertensive 
patients are not consistent with high levels in some studies but normal or low levels in 
others (269-271). There does, however, appear to be a subset of hypertensive patients, 
those with associated low plasma renin levels, in whom AVP is consistently elevated. 
These patients include the elderly, African-Americans as well as patients with chronic 
renal failure and DM (27, 29, 272, 273). The importance of AVP as a pressor agent in 
low-renin hypertension has been shown in a number of studies. The first used an IV 
injection of a peptide ViR antagonist and demonstrated that in elderly and in black 
participants the depressor responses to this antagonist infusion were significantly greater 
than in young and white volunteers (274). A second similar experiment showed that a
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single IV injection of a ViaR antagonist lowered arterial BP in African-Americans but not 
in Caucasians (by 28±4 mmHg in African-Americans versus 5±3 mmHg in Caucasians, 
P<0.05 (29). A population-based study has shown that plasma AVP concentrations display 
a discemable relationship with arterial BP, particularly when renin levels are low (275). 
Furthermore, a single dose of a peptide ViaR antagonist in diabetic hypertensive patients 
with autonomic neuropathy led to a significant reduction in diastolic orthostatic BP, but 
not supine BP, suggesting that AVP plays a major role in modulating BP in the upright 
posture in these patients (276). Published data on the effect of non-peptide AVP receptor 
antagonists in human BP control has thus far been very limited. A study in essential 
hypertension demonstrated that plasma AVP levels were similar between normotensive 
and hypertensive subjects and that OPC 21268 did not produce any significant changes in 
BP or heart rate in these patients. This finding was independent of a low or high salt diet 
(277). Another group was able to demonstrate that a single oral dose of non-peptide ViaR 
antagonist, SR49059, given to a group of patients with mild essential hypertension resulted 
in a transient vasodilatory effect only, and no sustained BP reduction was seen (278). This 
group of patients included 1 2  black as well as 1 2  white subjects and a failure to see a fall in 
BP in the low-renin African-American group is in direct contrast to many of the studies 
outlined above. These discrepancies have been explained in terms of different antagonists 
used, different conditions of BP monitoring (supine verus orthostatic) and different 
demographic conditions such as age and gender.
Thus with regards to hypertension and AVP in man it seems likely at this stage that AVP 
plays a significant role in a subgroup of patients with low-renin hypertension such as the 
elderly, African-Americans and diabetic hypertensive patients. Currently, however, there is
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little published data on long-term A W  receptor antagonism that would support this 
argument and this is something that clearly needs to be addressed.
1.5.2 Diabetes Mellitus (DM)
DM is a growing health concern of epidemic proportions with greater than 1.4 million 
people in the UK currently diagnosed (279) and an estimated further million who have the 
disease but remain unaware (280, 281). Moreover it is estimated that the prevalence of 
DM is likely to double between 1995 and 2010 (282). Diabetic nephropathy represents a 
major complication of DM and develops in about one-third of patients within 10-20 years 
after the onset of the disease and leads in most cases to end-stage renal failure with its 
associated high morbidity, mortality and associated national health expense (283-286). 
Indeed, diabetic nephropathy is the leading cause of end-stage renal disease in the Western 
world (286-288). The incidence of CVD is very high amongst diabetics with an annual 
mortality rate in the type 2 patient of as much as 4% per year as compared to an annual 
mortality rate of less than 1% in an age matched non-diabetic population (289). Although 
better blood glucose control and advances in drug therapy, such as the introduction of ACE 
inhibitors, reduces the likelihood of renal failure and cardiovascular complications it does 
not completely prevent them (15, 290). More effective strategies are therefore required. 
Several studies have shown that A W  is elevated in DM but the consequences of this have 
received little attention (23, 51,125).
1.5.2.1 DM and an elevated plasma A W
More than twenty years ago Zerbe et al were able to demonstrate that patients with type 1 
DM and ketoacidosis had a marked elevation in plasma A W  concentration (23). Although
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the degree of this elevation does vary from one study to another, all subsequent studies in 
humans with either type 1 or type 2 DM have confirmed this finding (24, 25, 291). In rats, 
streptozotocin (STZ)-induced DM results in a 2-to7-fold elevation in plasma AVP (51, 
292-294) with there being a strong positive correlation between the dose of STZ given, the 
degree of resultant hyperglycaemia and the plasma AVP concentration seen. With a 
genetic form of DM (dbdb), an animal model for type 2 DM, rats exhibit an even greater 
elevation (293). In both rats and humans the correction of hyperglycaemia is accompanied 
by a significant reduction in plasma AVP and thirst. In DM the degree of elevation or 
reduction in plasma AVP, seen in response to various stimuli, is exaggerated. For 
instance, the rise in plasma AVP after hypertonic saline infusion (292) or after cigarette 
smoking and the fall in AVP observed after induction of hypoglycaemia is greater in 
diabetics as compared to control subjects (295). The usual circadian rhythmicity in plasma 
AVP observed in normal rats is lost with uncontrolled type 1 DM (296) and the AVP 
content of the neurohypophysis is reduced in patients with uncontrolled type 2 DM (297).
What factors might be responsible for this AVP elevation seen in DM? Thus far, several 
studies have investigated this (23, 292, 298, 299). During hyperglycaemia AVP remains 
inappropriately high, even when plasma sodium is in the hyponatraemic range, and might 
suggest a resetting of the hypothalamic “osmostat”. It could be suggested that insulin 
deficiency transforms the osmoreceptor from glucose-insensitive to glucose-sensitive for 
its role in AVP release. Hyperglycaemia itself, however, does not seem responsible for the 
resetting of this “osmostat” as an IV infusion of hypertonic dextrose will not increase 
plasma AVP in diabetic subjects or healthy controls (300, 301). On the other hand, abrupt 
discontinuation of an insulin infusion in type 1 diabetics increases plasma AVP and this 
increase is delayed and significant only after 4 hours, despite the rapid rise in plasma
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glucose seen (299). Besides glucose, amino acids represent other osmotically active 
solutes that are elevated in DM (302-304). This disturbance is secondary to the role that 
insulin normally plays in amino acid uptake into cells through their membranes (305, 306). 
It is possible that a chronic elevation in the plasma level of some amino acids could play a 
role in the high AVP secretion of DM (307). Plasma amino acid concentrations increase 
by 2-3mmol/l after a high protein meal while concentrations of sodium and urea remain 
little changed. Interestingly such a meal also triggers an increase in plasma osmolality and 
AVP and therefore it can be postulated here that amino acids represent the most likely 
osmotically active substances to trigger this (308). They may also play a role therefore in 
the elevated AVP levels seen in DM. Amino acid levels are also significantly disturbed in 
chronic renal failure (CRF) a disease that is also associated with an elevation in plasma 
AVP (267, 309).
1.5.2.2 Acute physiological benefits of an elevated plasma AVP in DM
In the short-term an elevation in plasma AVP plays a vital role in limiting the glucose- 
induced water loss and dehydration associated with uncontrolled DM. In uncontrolled DM 
the osmolar load is largely enhanced by glycosuria, glucose alone representing more than 
half of the excreted solutes (310). Under the influence of AVP, a considerable amount of 
the body’s water, that is obligatorily filtered along with this glucose, is able to be 
reabsorbed in the CD and to such an extent that the final concentration of glucose in urine 
is far in excess of that in plasma (311). The AVP elevation in DM represents an 
appropriate adaptation by limiting, to some extent, the amount of water required for the 
excretion of a markedly elevated load of solutes (312).
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1.5.2.3 Chronic deleterious effects of an elevated plasma AVP in DM
AVP is known to be elevated in chronic renal disease (272). Several studies have strongly 
suggested that when sustained for long periods of time this continuous, high urinary 
concentrating activity, may become deleterious to the kidney (313). Chronic infusion of 
AVP or its V2 R agonist dDAVP, in normal rats, induces glomerular hyperfiltration (314, 
315) and kidney hypertrophy (316) and increases urinary albumin excretion (312). On the 
other hand, a chronic reduction in urinary concentrating ability slows the progression of 
CRF and reduces glomerulosclerosis, albuminuria and tubulointerstitial injury in BB rats 
with five-sixths nephrectomy (317). The mechanisms of these deleterious effects of AVP 
are not yet understood. AVP causes mesangial cell proliferation and extracellular matrix 
production via the ViaR (318, 319). AVP is involved in the renal regulation of BP control 
and contributes to increased renovascular resistance through ViAR-induced 
vasoconstriction in the vasa recta of the renal medulla (106, 116) (320). AVP, through its 
actions on the renal V2 R, contributes to fluid retention and hyponatraemia. Since AVP is 
elevated in DM, and because of previously described deleterious effects of AVP in CRF, it 
seems likely that AVP is playing some role in the progression of renal disease in DM.
1.5.2.4 AVP receptors in DM
A recent study in type 1 diabetic patients demonstrated renal resistance to AVP in subjects 
with poorly controlled blood sugars and, that the severity of this, was inversely 
proportional to the degree of glycaemic control (321). This may go some way to 
explaining why those patients with poorly controlled DM fare less well in diabetic 
ketoacidosis (321). Whether this resistance effect is due to down-regulation of the V2 R 
number (B max), reduced V2 R affinity for AVP (Kd) or a change at the level of medullary 
AQP-2 remains unclear (321). A study in Sprague Dawley (SD) rats, made diabetic for 2
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weeks, did not demonstrate any alteration in renal V2 R Bmax or Kd, while Bmax for both 
renal and hepatic ViaRs were down-regulated with no alteration in Kd (51). In the db/db 
mouse model of genetic, or type 2 DM, after 10 weeks there was a down-regulation of 
hepatic ViaR mRNA while the brain message for the same receptor remained unchanged 
(322).
Early DM is characterised by impaired responses to pressor hormones and pressor receptor 
down-regulation. Whether these regulatory effects are maintained long-term and are still 
pertinent with associated hypertension remains to be determined and is part of the remit of 
this thesis.
1.5.2.5 AVP receptor antagonists- their potential role in the management of DM
The relatively recent availability of non-peptide, orally active analogues has allowed for 
study of the effects of chronic AVP receptor blockade in DM. Thus far these studies have 
been limited but have provided good evidence for the importance of AVP in a number of 
deleterious effects of this disease. For instance, a study in BB and control rats with STZ- 
DM showed urinary albumin excretion more than doubled in controls but rose by only 
34% in the BB rats with DM. This was accompanied by a less intense kidney hypertrophy 
in the BB rats (312). In a short-term study in type 2 diabetics, ViaR antagonism using 
OPC 21268 significantly reduced microalbuminuria without affecting BP (323). In a 
model of focal glomerulosclerosis in hypercholesterolaemic rats with unilateral 
nephrectomy, OPC 21268 attenuated proteinuria and decreased glomerulosclerosis (324). 
On the other hand, a recent study using the ViaR antagonist SR 49059 demonstrated no 
change in diabetes-related vascular changes in the mesenteric arterial bed of the SD rat 
(294). The role of V2 R antagonism has been assessed in a 9 week study where STZ-DM
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rats were given the selective, non-peptide, orally active V2 R antagonist SR 121463A. This 
treatment totally prevented the rise in albuminuria with time seen in untreated DM rats and 
blunted the DM-induced rise in kidney mass (325).
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1.6 THE RENIN ANGIOTENSIN SYSTEM (RAS)
As compared to that of AVP, the role of the renin angiotensin system (RAS) in the 
regulation of BP and in CVDs has been well characterised. ACE inhibitors are widely 
used in the treatment of hypertension and are currently the ‘gold standard’ drug group used 
in the management of diabetic nephropathy (1,9). In chapter 5 the ACE inhibitor ramipril 
will be given alone and in combination with ViaR antagonist OPC 21268. For these 
reasons a basic overview of the RAS will now be given.
The RAS is known to function on a number of levels, as a systemic circulating hormone, a 
local paracrine/autocrine system and as a neurotransmitter within the CNS (326-329). The 
primary active hormone, Ang II, is an octapeptide and is produced as the end result of the 
enzymatic cascade as shown in figure 1.5.
Angiotensinogen is a large glycoprotein, classically produced within the liver, and its 
secretion is stimulated by hormones such as glucocorticoids, steroids and by Ang II itself. 
Once released into the circulation this large precursor molecule undergoes enzymatic 
cleavage by renin to form Ang I. Renin is released from the juxtaglomerular cells of the 
kidneys in response to reductions in blood volume, BP or sodium concentration and renin’s 
cleavage of angiotensinogen is the rate-limiting step in this cascade. Finally, Ang I is 
cleaved by the membrane-bound metalloproteinase ACE to form Ang II (330).
Ang II is one of the most potent vasoconstrictors in humans. It increases BP through 
vasoconstriction and also via direct and indirect actions at the kidney. Ang II acts directly 
in the proximal renal tubule to increase sodium and water reabsorption and indirectly 
stimulates the release of aldosterone from the adrenal cortex to result in the retention of
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sodium and water in the distal tubules and CDs (331-334). Ang II also acts centrally to 
promote thirst, release AVP and stimulate the sympathetic nervous system (335). Within 
the heart Ang II acts as a mitogen, potently stimulating hypertrophy of myocytes (336) and 
hyperplasia of cardiac fibroblasts (337). Ang II acts through one of 2 receptor subtypes the 
angiotensin type 1 receptor (ATiR) and the angiotensin type 2 receptor (AT2R). The ATiR 
is predominant in the adult and mediates the biological actions of Ang II, as outlined 
above, through a variety of signal transduction mechanisms including the activation of 
phospholipase C and A2 and inhibition of AC (338). AT2RS are predominant in the fetus, 
but are also present in adult tissues such as the adrenals, ovaries, uterus and brain (338). 
They exert biological effects generally opposed to those mediated by the ATiRs and are 
currently thought to activate the tyrosine kinase second messenger system (339). Specific 
receptor blockers are currently available and the ATiR blockers such as losartan, 
candesartan and irbesartan are increasingly being used clinically as alternatives to ACE 
inhibitors. AT2R blockers are available for use in the laboratory and include PD 123177 
and PD 123319 (340).
ACE, as stated earlier, is a membrane bound metallopeptidase and is produced most 
notably in the endothelium of somatic cells but also within parenchyma and inflammatory 
cells. The enzyme is normally (>90%) anchored to the cell membrane by a hydrophobic 
domain and has a large extracellular domain containing the 2  extracellular catalytic sites 
that are inhibited by ACE inhibitors (341). A lower molecular weight form of ACE, with a 
single catalytic site, is found in germinal cells (342). ACE can also be found floating free 
within plasma and other body fluids after post-translational cleavage by the enzyme 
secretase has removed the catalytic from the anchoring transmembrane and cytosolic 
domains (343). ACE has broad substrate specificity in that, as well as the cleavage of Ang
Chapter 1: Literature review 53
I, it can also inactivate other peptides such as bradykinin and substance P and it is this that 
produces the side effects of angioedema and cough associated with ACE inhibitor 
treatment (344, 345). Ang II can also be formed via alternative non-ACE routes and can 
be produced directly from angiotensinogen via the action of non-renin enzymes such as 
tissue plasminogen activator (tPA), cathepsin G and tonin (346).
All components of the RAS shown have been described in a wide variety of tissues 
including kidney, brain, heart and adrenal gland and this lends weight to the argument that 
Ang II can exert its biological actions not only as an endocrine hormone but also in a 
paracrine and autocrine fashion (330).
Activation of the RAS with increased local production of Ang II and increased bradykinin 
degradation has important implications in a number of CVDs. Conditions such as 
hypertension and DM result in endothelial dysfunction and are associated with the 
activation of ACE and in particular tissue ACE (330). Endothelial dysfunction describes a 
broad spectrum of abnormalities including disruption of the balance of vasodilation and 
vasoconstriction, vascular smooth muscle growth and increased oxidative stress and 
inflammatory markers (330). In essential hypertension increased plasma renin activity and 
hence increased Ang II has been implicated as a risk factor that contributes to the 
maintenance of the disease state and as a risk factor for vascular injury to the heart, kidney 
and brain (347). In DM levels of ACE and Ang II are also elevated, although often with a 
low to normal plasma renin (348). Proteinuria is a common sequelae to both of the above 
CVDs and, as well as being a principal predictor of renal damage, is also a strong marker 
for CVD (349). Treatment with ACE inhibitors has been shown consistently to reduce 
proteinuria in these patients as compared to other antihypertensive agents that lower BP to
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a similar level (350). The lack of an antiproteinuric effect by other antihypertensive agents 
suggests that renal protection and hence CVD protection may occur through a BP- 
independent mechanism. Much evidence for this hypothesis exists in the literature from 
large multicentre clinical trials such as the HOPE (Heart Outcomes Prevention Evaluation 
Study) (351), CAPPP (Captopril Prevention Project) (352) and ABCD (Appropriate Blood 
Pressure Control in Diabetes) trials (353).
Irrespective of the huge impact that ACE inhibitors, and now also ATiR blockers, have 
had on the treatment strategies for CVDs such as hypertension and DM, mortality and 
morbidity rates remain unacceptably high. It is evident therefore that novel therapeutic 
approaches are necessary to improve quality of life and survival amongst these patients.
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Figure 1.6: The renin angiotensin cascade leading to the formation of Ang II and its 
biological actions at the ATi and AT2 RS.
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1.7 THESIS HYPOTHESIS
As this review highlights there is strong evidence that AVP does have a part to play in the 
pathogenesis of CVDs but that its precise role remains unclear. To date, the regulation of 
AVP and its receptor system in long term DM, and in particular that associated with 
hypertension, has yet to be established. Once the regulation of the AVP system in this 
disease becomes clearer then any potential role for the blockade of AVP receptors by non­
peptide receptor antagonists can be elucidated. The development of these specific, non­
peptide AVP receptor blockers, as an additional treatment strategy for CVDs, is currently 
at a very early stage and new possible drugs are continually being discovered and 
characterised. ACE inhibitors, as described above, are well established in their role as 
antihypertensive agents, while V iaR antagonists alone are known not to lower BP in the 
adult hypertensive rat. Combination therapy with the 2 treatment groups has been shown 
not to be additive in the developmental phases of hypertension in adolescent SHR but has 
never been studied in the adult animal with established hypertension. Therefore the aims 
of this thesis are as follows:
1. To study, in rat, a novel group of 5 AVP non-peptide receptor antagonists made 
available from industry, and in particular to characterise in vitro and in vivo the drug 
whose agonist displacement profile most closely resembles that of AVP itself.
2. It is hypothesised that chronic dual ACE enzyme and V iaR inhibition will have additive 
effects in experimental hypertension that will not be predicted by selective ACE or V iaR 
inhibition. This thesis studied the effects of each treatment alone, and in combination, on
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SBP (via telemetry), organ weights, metabolic, biochemical and hormonal parameters in a 
hypertensive rat model.
3. It is hypothesised that there is disregulation of the AVP receptor system in long 
standing experimental hypertensive DM. This thesis looked at the regulation of AVP and 
its ViAR, at the mRNA and protein level, in a rat model combining hypertension and 8  
weeks of STZ-DM.
Chapter 2
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2.1 ETHICS
All experimental procedures involving animals were approved by the Austin and 
Repatriation Medical Centre Ethics Committee and were performed according to the 
National Health and Medical Research Council of Australia guidelines for animal 
experimentation.
Rats were obtained from the Austin Biological Research Laboratories, Austin and 
Repatriation Medical Centre, Melbourne, Australia. Animals were housed at 23 to 25°C in 
a 1 2 -hour light/dark cycle with access to a standard rat chow (0 .6 % sodium, 2 % chloride, 
2% calcium, Norco, Melbourne) and tap water ad libitum, unless otherwise indicated.
The spontaneously hypertensive rat (SHR), first developed in 1963, resulted following 
genetic inbreeding of rats with higher than normal blood pressure (354, 355). Analogous 
to essential hypertension the SHR develop cardiac hypertrophy in response to a slow and 
progressive rise in arterial pressure and peripheral resistance (figure 2.1) (356, 357). 
Increases in arterial pressure and peripheral resistance follow a characteristic pre­
hypertensive phase (up to 6  weeks old), a developmental phase (6 - 1 2  weeks old) and an 
established phase where systolic blood pressure (SBP) is elevated to approximately 200- 
220mmHg by 16 weeks (figure 2.1). As there is no direct genetic control for the SHR it 
was decided that Sprague Dawley (SD) rats would be used as the normotensive control to 
the SHR. To confirm their inbred status, laboratory SHR colonies are regularly tested for 
polymorphic markers.
2.2 ANIMAL MODELS
2.2.1 Spontaneously hypertensive rat
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Figure 2.1 The development of blood pressure in the SHR. Modified from (50).
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2.2.2 Streptozotocin-induced diabetes mellitus (STZ-DM)
The STZ-DM rat provides a useful and well-characterised model in which to study DM 
(358). These animals develop proteinuria, hypertension, glomerular basement membrane 
(GBM) thickening, mesangial expansion, glomerular hypercellularity and tubulointerstitial 
changes. Studies using this animal model have clearly demonstrated that various 
interventions including intensified glycaemic control and insulin, pancreatic 
transplantation and ACE inhibition will attenuate albuminuria and renal injury (359-361). 
However this model is not associated with hypertension, a common accompaniment of 
renal injury in man (12-14). Since most patients with diabetic nephropathy have 
associated systemic hypertension, it is important to also have a model of diabetic 
nephropathy with systemic hypertension. To address this, STZ-diabetes was induced in 
the SHR. This model developed an accelerated from of renal injury with rapid onset of 
albuminuria and more severe glomerular ultra structural injury (362).
SHR aged 8  weeks and weighing between 200 and 250g were fasted overnight and 
randomised to receive either STZ, at a dose of 45mg/kg, or citrate buffer (non-diabetic 
controls) by intravenous injection in the tail vein. Diabetic state was confirmed 48 hours 
later by tail vein glucose readings (Advantage, Boeringer Mannheim, Munich, Germany). 
Only animals with a plasma glucose level>17mmol/l were included in the study. Diabetic 
animals were treated with daily 4 Units, Ultralente Insulin (Novo, Copenhagen, Denmark) 
subcutaneously to allow weight gain and prevent ketoacidosis without rendering the 
animals euglycaemic. Tail vein glucose readings were taken every second week to 
confirm on-going diabetic state. Again, any animal with a plasma glucose<17mmol/l, at 
any stage, was excluded from the study.
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2.3 DRUGS
Drugs A-E are vasopressin (AVP) receptor antagonists and were a generous gift from R. W 
Johnson Pharmaceutical Research Institute, (New Jersey. USA). OPC 21268, a 
vasopressin type 1 A receptor (ViaR) antagonist and OPC 31260, a vasopressin type 2  
receptor (V2 R) antagonist, were generous gifts from Otsuka Pharmaceutical Co. Ltd 
(Tokushima, Japan). YM087, a mixed Via and V2 R antagonist, was a gift from 
Yamanouchi Pharmaceutical Co. Ltd (Japan). Ramipril, an ACE inhibitor, was purchased 
from Aventis Pharmaceuticals (New Jersey, USA). Perindopril, an ACE inhibitor, was 
purchased from Servier Pharmaceutical Co. Ltd (Cedex, France).
2.4 CHEMICALS
Aprotinin, STZ and Tris-HCL were obtained from Sigma Chemical Co (St Louis, USA) 
and bovine serum albumin (BSA) from CSL Ltd. (Victoria, Australia). AVP was obtained 
from Pensula laboratories Inc. (California, USA). All other reagents were purchased from 
BDH Chemicals (Victoria, Australia) or Ajax chemicals (New South Wales, Australia).
2.5 IN VIVO TECHNIQUES
2.5.1 Tail cuff SBP measurements
SBP was measure by tail-cuff plethysmography (38L flatbed recorder, model 229 
Amplifier, IITC Life Science, Woodland Hills, USA) in warmed, lightly restrained rats.
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2.5.2 Telemetry
SHR, aged eight weeks, weighing between 180-220g were synchronized to 12:12 hrs of 
light (0700-1900) and dark (1900-0700) for at least 5 days. Prior to implantation the 
devices (Data Sciences International, St. Paul, MN, USA, model TA11PA-C40) were 
calibrated to read within ±3mmHg. The rats were anaesthetized with a combination of 
Nembutal (Rhone Merieux, Pinkemba, Australia) 30mg/ml, Brietal Sodium (Eli Lilly, 
Indianapolis, USA) 40mg/ml and Atropine Sulphate (Delta West Pty. Ltd., Bentleigh, 
Australia) 6 mg/ml and injected with a dose of 5ml/kg intraperitoneally. A 3-4cm 
abdominal incision was made and the abdominal aorta exposed and clamped inferior to the 
bifurcation of the renal artery. An additional clamp was also placed superior to the femoral 
artery bifurcation to prevent backflow from the legs. The sensor’s catheter was inserted 1 
cm into the clamped area, glued into place with Histoacryl® (Braun, Mengulsen, 
Switzerland) and the radio-frequency transmitter sutured to the abdominal wall. Each rat 
received post-operative pain relief in the form of morphine sulphate (David Bull, 
Mulgrave, Australia) (5mg/kg) intraperitoneally. After allowing a minimum of 5 days for 
full recovery the rats were assigned to treatment groups. Each rat was housed individually 
and exposed to standard food chow and water ad libitum, with the plastic cage (30cm x 
40cm xl3cm) placed on top of a receiver (RPC-1) connected to a BCM-100 consolidation 
matrix. This receiver then transmitted parameter and waveform information to the 
Dataquest Gold Acquisition system (Data Sciences International, St. Paul, MN).
2.5.3 Metabolic measurements
Rats were placed into metabolic cages (Iffa Credo, L’Arbresele, France) for 24 hours prior 
to study days to allow for acclimatisation. On day of study, rats were weighed and food 
and water measured at the beginning of the 24-hour study period. At the end of the 24-
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hour period, food and water intake were measured and urine was collected for analysis of 
urinary volume, sodium and osmolality.
2.6 IN VITRO TECHNIQUES
2.6.1 Radio ligand preparation
2.6.1.1 Iodination of the AVP Vi aR antagonist d(CH2 )5 ,sarcosine7-AVP
The radioligand used to localise the ViaR was 125I[p-mercapto-p,p-cyclopentamethylene 
propionic acid), 7-sarcosine]-AVP (abbreviated, I[d(CH2 )s,sarcosine ]AVP) (Auspep, 
Melbourne, Australia). d(CH2 )s, sarcosine7-AVP is a specific ViR antagonist with potent 
antipressor activity (pA2 =7 .9 3 ) and minimal antidiuretic activity (0.12U/mg) or 
antioxytocic activity (pA2=6.13) (105, 363, 364). d(CH2 )s, sarcosine7-AVP was radio- 
iodinated by modification of the chloramine T method (105, 365). The reagents for the
n
iodination were dissolved in 0.25mol/l borate buffer pH 7.5 and d(CH2 )s, sarcosine -AVP 
was iodinated at room temperature using lmCi of I (Amersham Radiochemicals, 
Amersham, England) and chloramine T (5mg/ml). The reaction was stopped after 20 
seconds with sodium metabisulphite. The reaction mixture was then transferred onto a 
Sep-pak, C l 8  cartridge, which had been pretreated concurrently with 2mls of 0.08%
trifluoroacetic acid (TFA). After 5 successive washes with 2mls of 0.08% TFA, the
sample was eluted with 80% acetonitrile containing 0.08% TFA. The eluate was then 
dried under a steady stream of high-purity nitrogen and stored overnight at 4°C. On the 
following day the sample was reconstituted in 350pl of mobile phase (32% acetonitrile 
with 0.08% TFA) for high performance liquid chromatography (HPLC) purification 
(Waters Associates, Milford MA). Fractions from the largest peak were pooled and dried
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down under a steady stream of high purity nitrogen and then resuspended in 0 . 0 1  mol/1  
acetic acid containing 0.1%BSA.
2.6.1.2 Radiolabelled AVP V2 R antagonist [3 H]des-Gly-NH2 9 -d(CH2 )s[D-
Ile2 ,Ile4]AVP
The selective V2 R antagonist radioligand, [Phe-3 ,4 ,5 -3H]9 -des-Gly-NH2 , I-(p-mercapto- 
P,p-cyclopentamethylene propionic acid) [2-D-Ile, 4-Ile]AVP (abbreviated, [3H]des-Gly- 
NH2 9 -d(CH2 )5 [D-Ile2 ,Ile4 ]AVP) was obtained from Dupont Company (Boston, Mass. 
USA)(specific activity range: 45-80 Ci/mmol) (366). The radiochemical purity of this 
antagonist is checked using HPLC on a Vydac proteins and peptides Cl 8  column with the 
mobile phase 0.2% TFA:acetonitrile (60:40). The rate of decomposition, stored at -20°C, 
is 1% every 3 months.
2.6.1.3 Iodination of the ACE inhibitor MK-351A
p r
I MK-351A was the radioligand used to assess ACE inhibition by in vitro 
autoradiography. MK-351A is a derivative of the ACE inhibitor lisinopril. It was 
iodinated by the chloramine T method and purified by SP Sephadex C25 column 
chromatography as previously published (367).
2.6.2 In vitro autoradiography
At the conclusion of each experiment kidneys were snap frozen in isopentane at -40°C for 
in vitro autoradiography of AVP Via and V2 RS and ACE. Frozen tissue sections (20pM in 
thickness) were cut on a cryostat (Microm, Germany) at -20°C, thaw mounted onto 1%
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gelatin coated slides and dessicated at 4°C overnight to remove moisture before freezing at 
-80°C.
2.6.2.1 AVP ViaR in vitro autoradiography
Frozen slide mounted sections were equilibrated to room temperature and preincubated at 
4°C for 15 minutes in a 100mmol/l Tris-HCL buffer (pH 7.4) containing 10mmol/l MgCk 
and 0.1% BSA (buffer A). These slides were then transferred to separate slide mailers 
containing lOmls of incubation buffer (buffer A with 0.5mg/ml bacitracin and lOOIU/ml
n £
aprotonin) and approximately 35pmol/l I[d(CH2)s, sarcosine ]-AVP (1.4x10 cpm) for 16 
hours at 4°C. Non-specific binding was determined following parallel incubations 
containing 2pmol/l of unlabelled AVP. The binding reaction was terminated by four 
successive 30 second washes in ice-cold buffer A at 0°C followed by a 30 second wash in 
ice-cold distilled water. The slides were dried under cool air, loaded into X-ray cassettes 
and exposed to Agfa Scopix CR3 film (Agfa Gevaert, Ghent, Belgium) for 7-10 days. 
Quantitation of binding density was determined by computerised densitometry (MCID, 
Imaging Research, Ontario, Canada) using radioactive standards that were corrected for 
decay and fitted to calibration curves to convert density of the autoradiographs to d.p.m per 
mm2.
2.6.2.2 AVP V2R in vitro autoradiography
Frozen slide mounted sections were equilibrated to room temperature and preincubated at 
4°C for 15 minutes in a 100mmol/l Tris-HCL buffer (pH 7.4) containing 10mmol/l MgCl2  
and 0.1% BSA (buffer A). These slides were then transferred to separate slide mailers 
containing lOmls of incubation buffer (buffer A with 0.5mg/ml bacitracin and lOOIU/ml 
aprotonin) and 2nmol/l [3H]des-Gly-NH2 9 -d(CH2 )5 [D-Ile2 ,Ile4]-AVP for 60 minutes at
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20°C. Non-specific binding was determined following parallel incubations containing 
2pmol/l of unlabelled AVP. The binding reaction was terminated by four successive 30 
second washes in ice-cold buffer A at 0°C followed by a 30 second wash in ice-cold 
distilled water 0°C. The slides were dried under cool air, loaded into X-ray cassettes and 
exposed to flijibas H film for 10-14 days. The films were read in the Fujibas 3000 
phosphorimager (Fuji Photo Film Company Ltd, Tokyo, Japan). The generated computer 
images were then quantitated by computerised densitometry as described in section 2 .6 .2 .1 .
2.6.2.3 ACE in vitro autoradiography
Slide mounted sections were preincubated in 10mmol/l phosphate buffer, pH 7.4, for 15 
minutes at room temperature and then incubated in 10mmol/l sodium phosphate buffer, pH 
7.4, containing 150mmol/l sodium chloride and 0.2% BSA with 125I MK-351A 
(0.3mCi/ml) for 1 hour at room temperature. Non-specific binding was measured in 
parallel incubations containing 1 mmol/1 EDTA. Following incubation, sections were 
transferred through 4 successive 1 minute washes at 4°C in buffer. After the 1 minute 
washes sections were dried under cold air, placed in X-ray cassettes and exposed to Agfa 
Scopix CR3 X-ray film (Agfa Gevaert, Ghent, Belgium) for 1-4 days. Quantitation of 
binding density was determined as mentioned in section 2 .6 .2 .1 .
2.6.3 Renal membrane preparation
For both AVP VjA and V2 R binding studies, rats were killed by decapitation and kidneys 
were removed and membranes prepared as previously published (366, 368). Briefly, 
kidneys were dissected to remove cortex and coarsely minced, suspended in a 0.25mol/l 
sucrose buffer containing 20mmol/l Hepes, lmmol/1 EGTA (pH 7.4), 5pg/ml antipain and
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10pmol/l PMSF (buffer 1) at 4°C and homogenised using an Ultra-Thurrax (Jankel and 
Kunkel-IKA-WERK) dispenser at 18-20000rpm (3 times for 20 seconds). The 
homogenate was centrifuged at 1500rpm for 5 minutes at 4°C. The resultant supernatant 
was then centrifuged at 14000rpm for 20 minutes. The supernatant was then discarded and 
the pellet resuspended in 5mls of a 0.25mol/l sucrose buffer containing 20mmol/l Hepes, 
0.5mg/ml bacitracin and 100IU Aprotinin (buffer 2) and centrifuged at 14000rpm for a 
further 20 minutes. The supernatant was again discarded and the pellet resuspended in 1ml 
of buffer 2  and stored in liquid nitrogen prior to use.
2.6.4 Liver membrane preparation
For AVP V iaR binding studies, rats were killed by decapitation and livers removed and 
membranes prepared as previously described (369). Briefly, the connective tissue was 
removed and livers minced before being suspended in buffer 1 from section 2.6.3 at 4°C. 
Livers were then homogenised using an Ultra-Thurrax (Jankel and Kunkel-IKA-WERK) 
dispenser at 20-24000rpm (3 times for 20 seconds) and the homogenate was centrifuged at 
8500rpm for 15 minutes at 4°C. The pellet was discarded and the resultant supernatant 
was then centrifuged at 8500rpm for 15 minutes at 4°C. The pellet was discarded and the 
resultant supernatant was then centrifuged at 20000rpm for 60 minutes. The supernatant 
was then discarded and the pellet resuspended in lOmls if  buffer 2 from section 2.6.3 and 
centrifuged at 20000rpm for a further 60 minutes. The supernatant was again discarded 
and the pellet resuspended in 5ml of buffer 2 and stored in liquid nitrogen prior to use.
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2.6.5 Radioligand binding studies
2.6.5.1 AVP ViaR binding
The in vitro inhibition of selective ViaR antagonist radioligand binding was determined by 
incubating liver (60|j.g) or kidney (250pg) membranes from untreated rats in a buffer 
containing 100mmol/l Tris-HCL, 10mmol/l MgCk, 0.1% BSA, 0.5mg/ml bacitracin and 
lOOIU/ml aprotinin (pH 7.4) with 1 25I-labelled [d(CH2 )s, sarcosine7]-AVP (liver, 0.5nmol/l; 
kidney, 1 nmol/1) for 1 hour at 20°C. Bound and free ligand was separated by filtration 
through Whatman GF/B glass fibre filters using a Brandel automatic filtration apparatus 
(Biochem Research and Development Laboratories Inc, Gaithersburg, MD). The tubes and 
filters were washed 3 times with 2.51itres of filtration buffer (100mmol/l Tris-HCL, 
10mmol/l MgCb and 0.1% BSA (pH 7.4). The filters were then placed into Wassermann 
tubes and counted in a gamma counter (LKB 1260 Multi gamma II). Specific binding was 
calculated as total binding minus non-specific binding in the presence of lpmol/1  
unlabelled AVP. The in vitro displacement of 1 2 5I-labelled[d(CH2 )5 , sarcosine7]-AVP 
binding to liver or kidney membranes was measured in the presence or absence of AVP or 
experimental drug in the concentration range 0 .0 1 pmol/l to 0 .1 mmol/l.
2.6.5.2 AVP V2R binding
The in vitro inhibition of selective V2 R antagonist radioligand binding was determined by 
incubating kidney (500pg) membranes from untreated rats in a buffer containing 
100mmol/l Tris-HCL, 10mmol/l MgCh, 0.1% BSA, 0.5mg/ml bacitracin and lOOIU/ml 
aprotinin (pH 7.4) with 2nmol/l [3H]des-Gly-NH2 9 -d(CH2 )5 [D-Ile2 ,Ile4]-AVP for 2 hours at 
20°C. The incubation was stopped with the addition of 2.5mls of filtration buffer
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(100mmol/l Tris-HCL, 10mmol/l MgCk and 0.1% BSA (pH7.4) and bound and free ligand 
separated by filtration through Whatman GF/B glass fibre filters using a Brandel automatic 
filtration apparatus (Biochem Research and Development Laboratories Inc, Gaithersburg, 
MD). The tubes and filters were washed 3 times with 2.51itres of filtration buffer. The 
filters were dried and dissolved in 3.5mls of scintillant (Filter-count, Packard Instruments 
Co.Inc, Downers Grove, IL) and (3 radiation was measured using a Packard Tricarb 4530. 
Specific binding was calculated as total binding minus non-specific binding in the presence 
of 1 pmol/1 unlabelled AVP. Displacement of [3H]des-Gly-NH2 9 -d(CH2 )5 [D-Ile2 ,Ile4]-AVP 
binding to rat kidney membranes by unlabelled AVP or experimental drug was measured 
using 2nmol/l [3 H]des-Gly-NH2 9 -d(CH2 )5 [D-Ile2 ,Ile4]-AVP in the absence and presence of 
AVP or drugs A-E in the concentration range of 0.01pmol/l to 0.1 mmol/1.
2.6.5.3 AVP V iaR radioligand binding kinetics
The effect of DM on binding site density (Bmax) and the apparent affinity (Kd) of the liver 
Via and kidney ViaR was determined by analysis of the saturation binding of the selective 
ViaR radioligand 1 2 5I[d(CH2 )s, sarcosine7 ]-AVP. Liver and kidney membranes prepared 
from diabetic and control animals were incubated with 12 5I-labelled[d(CH2 )5 , sarcosine7]- 
AVP as described in section 2.6.5.1. Liver specific binding was approximately 70% and 
that for kidney approximately 50%. The Bmax and Kd values were determined by 
Scatchard analysis.
2.6.6 Blood collection
Rats were killed by decapitation and trunk blood collected into pre-chilled lithium heparin 
tubes (containing 100pi heparin, 25,000U/L) for the measurement of plasma AVP, sodium
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and osmolality and into pre-chilled tubes containing EDTA/aprotinin (kallikrein inhibitor 
500U/ml) for the measurement of plasma renin activity (PRA).
2.6.7 Hormonal and biochemical analysis
Plasma AVP was extracted using acetone and petroleum ether and measured by 
radioimmunoassay as previously described (370). The inter-assay and intra-assay 
coefficients of variation were less than 8 % and the limit of detection was approximately 
lpmol/1. PRA was measured by radioimmunoassay (371). The intra-assay coefficient of 
variation for the PRA assay was 9% and the specific binding 70%. Plasma ACE was 
measured using a fluorimetric assay (372). Plasma sodium was measured using an 
Instrument Laboratory Ilyte ion specific electrode analyse (Milan, Italy) and plasma 
osmolality was determined using an Advanced Instruments Micro-Osmometer model 330 
(Ma. USA). Rat glucose was assayed with a glucose oxidase method (373) and 
glycohaemoglobin was determined by an automated HPLC method (Primus CLC330) 
(374). Urinary albumin concentration was measured by a double-antibody 
radioimmunoassay involving a rabbit anti-rat antibody (Organon Teknika, Durham, NC) as 
previously described (375).
2.7 MOLECULAR TECHNIQUES
2.7.1 Real-time Polymerase Chain Reaction (PCR)
2.7.1.1 Extraction of total Ribonucleic acid (RNA)
Total RNA was isolated using the Rneasy Kit (Qiagen, Dorking UK). The RNA was then 
stored at -80°C until used. Briefly, 30mg of tissue was thawed and homogenised in 850pl
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of buffer RLT with 1% pmercaptoethanol, homogenised thoroughly and any precipitate 
discarded. The tissue RNA and deoxyribonucleic acid (DNA) were precipitated out by the 
addition of 70% ethanol. This was followed by DNase treatment and then a series of spins 
and ethanol elution steps. The RNA yield was then measured spectrophotometrically as 
follows. RNA purity and concentration were determined spectrophotometrically by adding 
2pi of the aforementioned RNA solution to 198pl of diethylpyrocarbonate(DEPC)-treated 
water and measuring its absorbance at 260 and 280nm. The amount of RNA in the original 
(undiluted) sample was calculated using the following formula:
Optical density (260nm) x dilution factor
RNA (pg/pl) = ---------------------------------------------------
1000
The RNA purity was calculated using the following equation:
Absorbance ratio = optical density (260nm)
optical density (280nm)
An absorbance ratio of 1.8-2.0 indicated a high degree of purity of RNA.
2.7.1.2 Reverse transcription of total RNA (cDNA synthesis)
0.3 pg of RNA was reverse transcribed in a reaction mixture which contained a final 
concentration of IX 1st strand buffer (0.1 mol/1 KCL, 6 mmol/l MgCL2 , 0.05mol/l Tris-HCL
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pH 8.4 and lOmmol DTT) (Boehringer-Mannheim, Germany), 500pmol/l of the 
deoxyribonucleotides dCTP, dGTP, dATP and dTTP (Progen Industries Ltd, NSW, 
Australia), 25 units of avian myoblastoma virus-reverse transcriptase (AMV-RT) 
(Boehringer-Mannheim, Germany) and sterile DEPC water in a final volume of 30pl. For 
control purposes the above reaction mixture was repeated in the absence of AMV-RT to 
validate synthesis from mRNA. Tubes were incubated at 25°C for 10 minutes, 60 minutes 
at 42°C and 5 mins at 95°C. Termination of the reaction was completed with the addition 
of 0.6ml EDTA (pH 8.0) and samples stored at -80°C until used.
2.7.1.3 PCR primers and probes
Specific AVP ViaR and V2 R cDNA oligonucleotide forward and reverse primer sequences 
and internal probes (FAM-chromophore) were designed using Primer Express 
applications-based primer design software (PE Applied Biosystems, CA, USA). TaqMan 
ribosomal RNA (rRNA) control reagents containing rRNA probe (VIC-chromophore) and 
forward and reverse primers were used for the detection of the housekeeping gene 18S 
rRNA. The primer and probe concentrations had previously been optimised for PCR use 
following the guidelines within the TaqMan Universal PCR master mix protocol 
(www.perkin-elmer.com.ab).
2.7.1.4 Plate set up and PCR reaction
25ng of cDNA for both liver and kidney was added, in duplicate, to each well of a 96-well
65)reaction plate to which was added 22.5pl of a reaction mix containing 12.5pl of TaqMan 
Universal PCR master mix (mix contains Amplitaq gold™, AmpErase UNG0, nucleotides 
dCTP, dATP, dGTP, dUTP, MgCb, glycerol, passive reference 1 and optimized buffer
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components), TaqMan® 18S probe (final concentration 175nmol/l), 18S forward primer 
(final concentration 20nmol/l), 18S reverse primer (final concentration 40nmol/l), 
Taqman® V iaR probe (final concentration 150nmol/l), V iaR forward primer (final 
concentration 900nmol/l), V iaR reverse primer (final concentration 900nmol/l) and filter 
sterilized DEPC-treated water. For each gene of interest a “no cDNA control” was added 
and 2 wells per 96-well plate were allocated to be “no template controls”. The reaction 
plate was capped, briefly spun and placed into the ABI Prism 7700 Sequence Detection 
System (PE Applied Biosystems CA, USA) and amplification conducted as follows: 
Firstly, 2min at 50°C for UNG® digestion followed by lOmin at 95°C to activate 
AmpliTaqGold® and then 40 cycles of 15 seconds at 95°C (denature) and 1 min at 60°C 
(anneal and extend).
2.7.1.5 Quantitation of PCR products
The method used to obtain relative gene expression data is the comparative CT method 
previously described by K. Livak (Applied Biosystems; Sequence Detector User Bulletin 
2). The C j value represents the “threshold cycle” for each gene. This method uses a 
“calibrator” sample for comparison of every unknown sample’s gene expression. It can be 
any sample chosen to represent IX expression of the gene of interest. In the diabetic study 
the calibrator sample is derived from the control SHR animals and gene expression of the 
diabetic SHR samples are compared to it. This method of relative quantitation is based on 
the assumption that the rate of Ct change and the rate of target copy change is identical for 
the gene of interest and the housekeeping gene and that a doubling of target results in one 
cycle decrease in the Ct.
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Firstly, 18S C t values were subtracted from ViaR Ct values, in each well, to give a ACt 
value. AACt values were achieved by subtracting the average ACt value for control rats 
from the ACt values of corresponding tissues from the DM rats. The expression of the 
V iaR genes in the diabetic animals relative to controls was evaluated using the formula 2 '
AACT
2.8 STATISTICAL ANALYSIS
Results are presented as mean±SEM. Data was analysed using one- and two-way analysis 
of variance (ANOVA) and the Fisher test where appropriate using the Statview® 
programme (Brain power Inc, Calabass, CA). Albuminuria data was logarithmically 
transformed before statistical analysis. Significant differences were obtained when p<0.05.
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3.1 SUMMARY
1. This chapter reports on study 1; the in vitro characterisation of non-peptide, orally 
active, vasopressin (AVP) Via and V2  receptor (ViaR and V2 R) antagonists, drugs A-E, in 
the rat and study 2; the in vivo characterisation of drug A.
2. Study 1. Drugs A-E caused a concentration-dependent displacement of the selective 
ViAR antagonist radioligand, 1 2 5I-labelled [d(CH2 )5 ,sarcosine7]AVP from ViaRs in both rat 
liver and kidney medulla membranes. The concentration of drug that displaced 50% of 
specific radioligand binding, or IC5 0 S for each drug, at the above receptors, was 
determined. Drug A was most effective followed by drugs E, C, D and B at the liver ViaR 
and drug A was again most potent at the renal ViaR followed by drugs E, C, B and D. 
Drugs A-E also caused a concentration-dependent displacement of the selective V2R 
antagonist radioligand [3H]desGly-NH2 9 [d(CH2 )s, D-Ile2, Ile4]AVP from V2RS in rat 
kidney medulla membranes, drug A being most potent followed by drugs E, B, C, and D.
3. Study 2: From study 1, drug A had a pharmacological profile most closely resembling 
AVP at both the Via and V2RS and therefore underwent further in vitro and in vivo 
characterisation in this second study.
Oral administration of Drug A (1, 3,10 mg/kg) dose-dependently inhibited AVP binding to 
liver ViaRs and kidney Via and V2RS at 2h. Significant inhibition was seen at the kidney 
Via and V2 R at lOmg/kg (P<0.01) but at 3mg/kg at the liver ViaR (P<0.05). Oral Drug A
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(10 mg/kg/day) inhibited AVP binding to liver Via (P<0.05) and kidney ViaRs (P<0.01) 
for 4h and to kidney V2 RS for 8 h (P<0.01; 2 and 4 hours. P<0.05; 8  hours).
Oral administration of Drug A (10, 30mg/kg) for 5 days in normotensive male and female 
rats caused a dose-dependent aquaresis on day 1 (acute response) (P<0.01 at lOmg/kg and 
30mg/kg for both male and female rats). By day 5 (chronic response) this aquaresis had 
diminished (P<0.05 at lOmg/kg in female rats and P<0.05 at 30mg/kg dose in male rats).
Oral administration of drug A (lOmg/kg) to normotensive female rats for 3 days did not 
have any hypotensive effects.
Plasma sodium and osmolality results were not elevated over control at either dose while 
plasma AVP was raised significantly at a dose of 30mg/kg (P<0.05 in female: P<0.01 in 
male). ViAR in vitro autoradiography demonstrated significant inhibition of binding of the 
selective ViAR antagonist radioligand, 1 2 5I-labelled [d(CH2 )5 ,sarcosine7 ]AVP, by drug A at 
the renal ViAR (P<0.05 at lOmg/kg and P<0.05 at 30mg/kg). V2 R in vitro autoradiography 
was not done in view of there being a clinically detectable V2 R diuretic response to both 
10 and 30mg/kg doses.
4. These results show that Drug A is an orally effective, ViA and V2 R antagonist that may 
be useful in the treatment of conditions characterised by vasoconstriction and fluid 
retention such as congestive cardiac failure (CCF).
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3.2 INTRODUCTION
CCF is a progressive disease characterised by neurohormonal activation, salt and water 
retention causing dyspnoea and oedema and ventricular dilation and hypertrophy, a process 
known as remodelling (376). Despite the impact of ACE inhibitors to attenuate this 
remodelling and improve survival (377, 378), the 5 year mortality rate remains 
unacceptably high. This has prompted the search for novel therapeutic approaches (379- 
381). AVP receptor antagonists represent one such new approach and several non-peptide 
AVP receptor antagonists have been developed. OPC 21268 and SR 49059 are selective 
ViaR antagonists. OPC 21268 blocks the pressor effects of AVP and lowers blood 
pressure (BP) in mineralocorticoid hypertension in the rat (8 6 , 123), whilst SR 49059 is a 
potent and selective ViaR antagonist in the human internal mammary artery (382). OPC 
31260, OPC 41061 and SR 121463A antagonise the effect of AVP at the V2R to cause an 
aquaresis (41-44). YM087 is a mixed AVP receptor blocker antagonising the action of 
AVP at both the Via and V2RS (46). In vivo, the ViaR antagonistic properties of YM087 
are demonstrated by its ability to block the pressor response to AVP in rats and dogs (169, 
383). In humans, a more recent study has shown that a single intravenous dose of YM087 
given to patients with advanced CCF (New York Heart Association class III and IV) 
resulted not only in a dose-dependent increase in urine output but also a significant 
reduction in pulmonary capillary wedge pressure and right atrial pressure when compared 
to placebo (266). This highlights the fact that it is the mixed Via and V2R antagonists in 
particular that are likely to play an important part in heart failure management in the near 
future. To date YM087 is currently the only available such drug and the search is on for 
others.
Chapter 3: Characterisation o f  novel non-peptide AVP antagonists 83
The high oral bioavailability of non-peptide AVP receptor antagonists allows long-term 
studies to be performed to further elucidate the role of AVP in cardiovascular diseases 
such as hypertension, CCF and renal failure and also in CNS disorders such as anxiety. 
The acute effects of an intervention do not necessarily predict long-term efficacy and to 
date there have been no studies assessing the long-term efficacy of any of the drugs under 
investigation here, specifically of drug A.
This study is split into two parts. Study 1 investigates the AVP receptor antagonist 
properties of Drugs A-E in vitro, in the rat, using selective AVP Via and V2 R radioligands. 
Study 2 further characterises drug A in vitro and in vivo, in the rat, using selective AVP 
Via and V2 R radioligands and assesses the effect of 5 days oral administration of drug A 
on BP, renal and plasma parameters in the normotensive rat.
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3.3 EXPERIMENTAL PROTOCOL
3.3.1 Ethics
This experiment was approved by the Austin and Repatriation Medical Centre Ethics 
Committee and performed according to the National Health and Medical Research Council 
of Australia guidelines for animal experimentation.
Both female and male Sprague-Dawley (SD) rats (250-300g) were used. Male SD rats 
(250-300g) were included in the 5 day metabolic parameter study. Systolic blood pressure 
(SBP) was measured in female rats using the indirect tail-cuff method as described in 
section 2.5.1.
Drugs A-E were a generous gift from R. W. Johnson Pharmaceutical Research Institute 
(New Jersey. USA). They were dissolved in organic solvent, dimethylsulfoxide (DMSO), 
and distilled water (ratio 4:1) and stored at a concentration of 1 mmol/1 at -20°C prior to all 
in vitro experiments. For animal gavage, drug was suspended in 0.5% methylcellulose 
(BDH, Poole, UK). A sonication step prior to gavage was included in later experiments as 
will be described. OPC 21268 was a gift from Otsuka Pharmaceutical Co. Ltd 
(Tokushima, Japan) and suspended in 0.5% methylcellulose. YM087, also known as 
conivaptan, was a gift from Yamanouchi Pharmaceutical Co. Ltd (Japan) and was 
suspended in 0.5% methylcellulose for gavage.
3.3.2 Animals
3.3.3 Drugs
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3.3.4 Radioligand
The selective ViaR antagonist 1 2 5I[l-(P-mercapto-p,p-cyclopentamethylene propionic 
acid), 7-sarcosine]AVP (abbreviated: 1 25I[d(CH2 )s, sarcosine7] AVP) and the selective V2R 
antagonist radioligand, [Phe-3 ,4 ,5 -3H]9 -des-Gly-NH2 , [l-(P-mercapto-p,p- 
cyclopentamethylene propionic acid) 2-D-Ile,4-Ile]AVP (abbreviated: [ HjdesGly-
NH2 9 [d(CH2 )5 , D-Ile2, lie4] AVP were used as described in section 2.6.1.
3.3.5 Study 1: In vitro characterisation of AVP receptor antagonists:
Drugs A-E
These experiments were designed to investigate the inhibition by drugs A-E of selective 
Via and V2 R antagonist radioligand binding to liver and kidney medullary Via and kidney 
medullary V2 RS using the protocols outlined in sections 2.6.5.1 and 2.6.5.2.
3.3.6 Study 2: Dose response and time course of AVP receptor binding with 
oral drug A
To assess the in vivo inhibition of drug A on AVP binding to liver and kidney medullary 
ViaRs and kidney medullary V2 RS, rats were gavaged with vehicle (0.5% methyl cellulose) 
or drug A (1, 3, 10 mg/kg) and killed 2h later for the dose response study (n=3-4 
rats/group).
For the time course study, rats were gavaged with lOmg/kg of drug A and killed at varying 
time points (0,1, 2, 4, 8,16, and 24 h) after gavage (n=3-4 rats/time point).
In each study, blood, liver and kidneys were collected. One kidney was snap frozen and the 
other used for immediate membrane preparation (section 2.6.3). Liver membranes were
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prepared (section 2.6.4). The effect of drug A on the binding characteristics of Via and 
V2 R.S in the kidney and of ViaR binding sites in the liver was determined by membrane 
binding and/or in vitro autoradiography (sections 2.6.2.1, 2.6.2.2, 2.6.5.1 and 2.6.5.2)
3.3.7 Effect of oral drug A on renal parameters and BP
3.3.7.1 Metabolic studies
Female rats: Initial problem solving experiments: Female SD rats (300g, n=24) were 
randomised to receive vehicle or drug A (lOmg/kg; 30mg/kg) by oral gavage. The initial 
batch of drug A had been finished in preceeding experiments and so a second was made 
available from the pharmaceutical company for this group of studies. On day 1 of 
treatment rats were placed into metabolic cages and water intake, urinary volume, urine 
sodium and osmolality measured for 24 h. A surprisingly low acute diuresis resulted and a 
30mg/kg bd dose of drug A was introduced, as well as the known acute aquaretic agents 
YM087 and OPC 31260. The resultant aquaresis with these known agents was good. The 
new batch of drug A was compared in vitro to the old by comparing the displacement of 
specific ViaR antagonist [d(CH2 >5 , sarcosine ] AVP in liver membranes and finally the new 
drug was sonicated prior to oral gavage for metabolic and BP studies.
On days 1 and 5 of treatment all rats were placed into metabolic cages and water intake, 
urinary volume, urine sodium and osmolality measured for 24 hours. On day 6  rats were 
then killed by decapitation and trunk blood collected as before. Kidneys were removed 
(n=4/group), rapidly frozen in dry-ice chilled isopentane and stored at -80°C until used for 
AVP ViaR in vitro autoradiography (section 2.6.2.1).
Chapter 3: Characterisation o f  novel non-peptide AVP antagonists 87
Male rats: Male SD rats (300g, n=24) were randomised to receive vehicle or drug A 
(lOmg/kg; 30mg/kg) by oral gavage. On days 1 and 5 of treatment all rats were placed into 
metabolic cages and water intake, urinary volume, urine sodium and osmolality measured 
for 24 hours. On day 6  rats were then killed by decapitation and trunk blood collected as 
before. Kidneys were removed (n=6 /group), rapidly frozen in dry-ice chilled isopentane 
and stored at -80°C.
3 3 .1 2  BP studies
Female SD rats (n=16) were gavaged with vehicle and lOmg/kg of drug A for 3 days and 
had SBP determined by tail cuff plethysmography on days 1 and 3, 120 minutes post 
gavage.
3.4 STATISTICAL ANALYSIS
Data were analysed by analysis of variance (ANOVA) using the Statview SE=Graphics 
programme (Brainpower, Calabasas, CA). Comparisons of group means were performed 
by Fisher’s least significant difference method. Data are shown as means±SEM unless 
otherwise specified. P<0.05 was viewed as statistically significant.
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3.5 RESULTS
3.5.1 Study 1. In vitro inhibition by drugs A-E of AVP binding
Each drug dose-dependently displaced selective V iaR antagonist radioligand I-labelled
n
[d(CH2 )5 ,sarcosine ]AVP at ViaRs in both rat liver and kidney medulla membranes (Figure 
1). The concentration of drug required to displace 50% of specific AVP binding, or IC5 0 , 
for each drug is given in table 3.1. Each drug also caused a concentration-dependent 
displacement of the V2 R antagonist [3H]desGly-NH2 9 [d(CH2 )s, D-Ile2, lie4] AVP to V2 RS in 
kidney medulla membranes (Figure 3.1). The IC5 0  for each drug, as compared to AVP, at 
the kidney V2 R, is also given in table 3.1.
From the above, drug A is seen to have the “best” pharmacological profile in that it most 
closely resembles AVP in its ability to displace the Via and V2 R selective radioligands. 
Specifically, the concentration of drug A that displaced 50% of specific AVP binding (IC5 0) 
was 5.8±0.1 nmol/1 for liver ViaR and 30±0.1 nmol/1 for kidney ViaRs (n=3-5). The IC5 0  
for AVP was 0.87±0.03 nmol/1 for liver ViaR and 3.9±0.14nmol/l for kidney ViaR (n=3- 
5). The IC5 0 for drug A, at the renal V2 R, was 3.22±0.1 nmol/1 (n=3-5) and that of AVP 
0.48±0.1 nmol/1, for kidney V2 RS (n=3-5) (Table 3.1).
3.5.2 Study 2. In vivo treatment with drug A on in vitro AVP binding
Oral administration of drug A (1, 3, 10 mg/kg) dose-dependently inhibited AVP binding to 
liver and kidney ViaR and kidney V2 RS at 2 h, with significant inhibition reached at the 
lOmg/kg dose (P<0.01)(Figure 3.2).
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After oral administration, drug A (10 mg/kg/day) inhibited AVP binding to liver (P<0.05) 
and kidney (P<0.01) ViaRs for 4h and to kidney V2 RS for 8 h (P<0.05). There was a 
rebound increase in V2 R binding at 24 hours (P<0.01)(Figure 3.3).
Drug A had no effect on plasma sodium or osmolality at any dose (1, 3 or 10 mg/kg), 2h 
following oral administration (Table 3.2) and drug A (10 mg/kg) had no effect on plasma 
sodium or osmolality at any of the time points studied (Table 3.2). Plasma AVP levels 
were significantly reduced by drug A at a dose of 10 mg/kg at the 8  and 24 hour time points 
following gavage (P<0.01) (Table 3.2).
3.5.3 Effect of oral drug A on renal parameters and BP
3.5.3.1 Metabolic studies
Female rats: Problem solving experiments. In initial metabolic studies an aquaresis was
not seen with an oral drug dose of less than 30mg/kg/day (data not shown) and this was
surprising in view of the preceding in vitro and in vivo data. Within the laboratory the 
mixed V 1A/V2R antagonist, YM087, and the selective V2R antagonist, OPC 31260, had 
previously been extensively studied and these drugs known to produce significant diuresis 
within the laboratory set up (46, 384). They were included in a repeat experiment (figure 
3.4). A predicted diuresis occurred with OPC 31260 (10mg/kg)(P<0.01) and YM087 
(1 mg/kg) showed a significant reduction in urinary osmolality (P<0.05) whereas, once 
more, drug A demonstrated no aquaresis until the higher dose of 30mg/kg (figure 3.4). An 
explanation beyond the set up of the metabolic cages was therefore sought.
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The metabolic studies were undertaken using a second batch of drug A, the first having 
been completely used during the initial in vivo and in vitro experiments. A possible 
explanation might be that the second drug had been manufactured under slightly different 
conditions and was somehow less potent then the first. To investigate this a liver ViaR 
displacement curve with AVP, old and new “batch” drug A, was undertaken. The curve 
produced by the second batch of drug A almost overlay that from the original (IC5 0  
old=4.02xl0nmol/l; IC5 0  new=6.61xl0nmol/l) and therefore this second theory was 
discounted (Figure 3.5).
In appearance the second batch of drug A was more granular than the first and to take this 
into account the metabolic studies were repeated once more with drug sonication prior to 
gavage. This brought the drug into a very fine suspension and was effective in promoting 
an aquaresis at lower doses of drug A (initial data not shown).
Acutely, female rats exhibited a dose-dependent increase in urine volume from a dose of 
lOmg/kg once daily (P<0.01). Urinary osmolality was significantly reduced from a dose 
of lOmg/kg (P<0.01). A significant increase in urinary sodium was seen at lOmg/kg 
(P<0.05) but not so at the higher dose of 30mg/kg (figure 3.6 & table 3.3). Chronically, 
after 5 days of daily oral treatment, there was a significant increase in urinary volume at 
lOmg/kg and 30mg/kg (P<0.05). Urinary osmolality was reduced at lOmg/kg (P<0.05) 
and 30mg/kg (P<0.01) (Figures 3.6 & table 3.2). Urinary sodium remained unchanged 
(figures 3.6 & table 3.3).
Male rats: On day 1, male rats exhibited a dose-dependent increase in urine volume at 
lOmg/kg/day (P<0.01). Urinary osmolality was significantly reduced at lOmg/kg and
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30mg/kg (PcO.Ol). No significant natriuresis was seen at any dose (figure 3.7 & table 3.3). 
Chronically, oral drug A (lOmg/kg and 30mg/kg), for 5 days caused no significant increase 
in urine output at lOmg/kg but did increase urine output at a dose of 30mg/kg (P<0.05). 
Urinary osmolality was similarly reduced by a dose of 30mg/kg (P<0.05). No natriuresis 
was seen after 5 days (figure 3.7 & table 3.3).
3.5.3.2 BP studies
Oral drug A had no effect on SBP in female normotensive rats on days 1 and 3 of 
treatment at a dose of lOmg/kg (Figure 3.8).
3.5.3.3 Plasma data
After 5 days of oral dosing plasma sodium and osmolality were unchanged in both the 
male and female rats. Plasma AVP was significantly elevated in female rats but only at a 
dose of 30mg/kg (5.4±0.4pmol/l versus 7.1±0.4pmol/l; vehicle versus drug A: P<0.05). In 
male rats, plasma AVP was significantly elevated at a dose of 30mg/kg only 
(8.5±0.8pmol/l versus 12.8±2.1pmol/l; vehicle versus drug A: P<0.01)(Table 3.4).
3.5.3.4 In vitro autoradiography
In female rats, after 5 days of oral treatment with drug A, significant inhibition of binding 
of the selective ViaR antagonist radioligand I-labelled [d(CH2 )s,sarcosine ]AVP by drug 
A at the renal ViaR was seen at lOmg/kg (P<0.05) and 30mg/kg (P<0.01)(Figure 3.9).
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Figure 3.1. Displacement of specific Via and V2 R antagonist binding with drugs A-E.
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Figure 3.1. Displacement of specific Via and V2 R antagonist binding with drugs A-E.
19SFigure 3.1 A. Displacement of the specific binding of the ViaR antagonist -I- 
labelled[d(CH2 )5 , sarcosine?]AVP from rat liver membranes by increasing concentrations 
of unlabelled AVP and drugs A-E.
1
Figure 3.IB. Displacement of the specific binding of the ViaR antagonist -I- 
labelled[d(CH2 )5 , sarcosine ]AVP from rat kidney medulla membranes by increasing 
concentrations of unlabelled AVP and drugs A-E.
Figure 3.1C. Displacement of the specific binding of the V2 R antagonist [3H]desGly- 
NH2 9 [d(CH2 >5 , D-Ile2, Ile4]AVP from kidney medulla membranes by increasing 
concentrations of unlabelled AVP and drugs A-E. B and Bo represent the amount of 
specific binding in the presence and absence of unlabelled compound respectively.
Each point represents the mean±SEM of 3-5 separate determinations performed in 
triplicate.
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Table 3.1. ICso’s of drugs A-E in rat.
1Liver and kidney membranes were prepared from untreated rats and incubated with " I- 
labelled[d(CH2 )5, sarcosine7]AVP in the presence of increasing concentrations of AVP and 
drugs A-E to determine IC50 at liver Via and renal ViaRs. Kidney medullary membranes 
from untreated rats were also incubated with [3 H]desGly-NH2 9 [d(CH2 )5, D-Ile2, Ile4]AVP in 
the presence of increasing concentrations of AVP and drugs A-E and IC50 values were 
obtained.
Each value represents the mean±SEM of 3-5 separate determinations performed in 
triplicate.
AVP/DRUG RECEPTOR TYPE
LIVER V1A RENAL V,A RENAL V2
(nmol/1) (nmol/1) (nmol/1)
AVP 0.87±0.03 3.4±0.1 0.5810.07
DRUG A 5.8±0.4 29±0.9 3.3111.4
DRUG B 740±9 1 0 2 0 1 1 0 57.310.8
DRUG C 157±7 46319 10611.3
DRUG D 520±7 1495112 3650114
DRUGE 138±6 354113 1810.9
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Figure 3.2. Dose response with oral drug A in rat
Figure 3.2A. Effect of orally administered drug A at 0, 1,3 and 10 mg/kg doses on the in
p f  n
vitro specific binding of I-labelled [d(CH2 )s, sarcosine ]AVP to liver ViaRs.
Figure 3.2B. Effect of orally administered drug A at 0, 1,3 and 10 mg/kg doses on the in
i o c  n
vitro specific binding of I-labelled [d(CH2 )s, sarcosine ]AVP to kidney medullary 
V iaRs.
Figure 3.2C. Effect of orally administered drug A at 0, 1,3 and 10 mg/kg doses on the in 
vitro specific binding of [3H]desGly-NH2 9[d(CH2 )s, D-Ile2, Ile4]AVP to renal medullary 
V2Rs.
Results are expressed as percentage change from initial binding at time zero. Each point 
represents the mean±SEM of three separate determinations performed in triplicate.
*P<0.05, **P<0.01 versus time zero.
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Figure 3.3. Time course of oral drug A in rat
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Figure 3.3. Time course of oral drug A in rat
Figure 3.3A. Effect of oral Drug A (lOmg/kg) on the in vitro specific binding of ViaR 
antagonist 125I-labelled [d(CH2 )s, sarcosine7]AVP to liver with increasing time from 
gavage.
Figure 3.3B. Effect of oral Drug A (lOmg/kg) on the in vitro specific binding of ViaR
i < i f  n
antagonist I-labelled [d(CH2 )s, sarcosine ]AVP to kidney with increasing time from 
gavage.
Figure 3.3C. Effect of oral Drug A (lOmg/kg) on the in vitro specific binding of V2 R 
antagonist [3H]desGly-NH2 9[d(CH2 )5 , D-Ile2, Ile4]AVP to kidney with increasing time 
from gavage.
Each point represents the mean±SEM of 3-4 separated determinations per time point 
performed in triplicate. *P<0.05, **P<0.01 versus time zero.
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Table 3.2. Effect of orally administered drug A (1,3,and 10 mg/kg) at 2 hours, and 
lOmg/kg at 1-24 hours at various time points on plasma sodium, AVP and osmolality.
Each value represents the mean±SEM of four separate determinations per time point 
performed in triplicate. **P<0.01 versus time zero.
Plasma sodium (mmol/1)
time vehicle 1 mg/kg 3mg/kg lOmg/kg
0 138±0.5
1 139±0.8
2 137±0.6 138±0.8 137±0.6 139±0.6
4 137±0.2
8 137±0.2
16 136±0.8
24 137±0.4
Plasma osmolality (mosm/kg)
time vehicle 1 mg/kg 3 mg/kg lOmg/kg
0 295±1.3
1 297±0.7
2 298.35±2.2 297.6±1.07 297.5±2.64 297±1.7
4 293±0.8
8 291±0.4
16 293±1.9
24 293±2.3
Plasma AVP (pmol/1)
time vehicle 1 mg/kg 3mg/kg lOmg/kg
0 4.7±0.1
1 4.1±0.3
2 3.5±0.6 2.9±0.6 2.0±0.1 4.1±0.4
4 4.3±0.5
8 3.3±0.3 **
16 3.9±0.3
24 2.8±0.1 **
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Figure 3.4. A comparison of the diuretic effects of increasing doses of drug A as 
compared to previously characterised AVP receptor antagonists
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Figure 3.4. A comparison of the diuretic effects of increasing doses of drug A as 
compared to previously characterised AVP receptor antagonists YM087 (mixed ViaR and 
V2 R) and OPC 31260 (V2 R selective antagonist).
Each point represents the mean±SEM of 4 separate determinations. *P<0.05, **P<0.01 
versus vehicle.
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Figure 3.5. A comparison of the displacement of specific V iaR antagonist binding by 
“old” and “new” drug A.
Displacement of the specific binding of the ViaR antagonist I-labelled [d(CH2 )s, 
sarcosine7] AVP from rat liver membranes by increasing concentrations of
A. Unlabelled AVP (■) and drug A-new( )
B. Drug A -old( ) and drug A-new( )
Each point represents one determination performed in triplicate.
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Figure 3.6. Results of metabolic studies to assess the acute effects of AVP V2R blockade 
by drug A.
Female SD rats were placed into metabolic cages on days 1 (acute) and 5(chronic) of 
treatment and A. Urine volume, B. Urine osmolality and C. Urine sodium were assessed 
for 24h.
Each point represents the mean±SEM of 6-8 separate determinations. *P<0.05, **P<0.01 
versus vehicle. BW=Body weight.
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Figure 3.7. Results of metabolic studies to assess the acute effects of AVP V2 R blockade 
by drug A
Male SD rats were placed into metabolic cages on days 1 (acute) and 5(chronic) of 
treatment and A. Urine volume, B. Urine osmolality and C. Urine sodium were assessed 
for 24h.
Each point represents the mean±SEM of 6-8 separate determinations. *P<0.05, **P<0.01 
versus vehicle. BW= Body weight.
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Table 3.3. Acute and chronic metabolic data represented as actual values for both male 
and female, acute and chronic studies.
Each point represents the mean±SEM of 6-8 separate determinations. *P<0.05, **P<0.01 
versus vehicle.
ACUTE FEMALE CHRONIC FEMALE
Vehicle 1 Omg/kg 30mg/kg Vehicle 1 Omg/kg 30mg/kg
Urine volume 
(ml/lOOg)
4.53±0.29 7.90+0.55** 14.36±1.51* 
*
5.37+0.40 6.95+0.52* 9.21+1.63*
Osmolality
(mOsm/kg)
2184±47 1364+103** 639+97** 1924+105 1524+112* 1094+164**
Sodium
(nmol/min/100g)
0.49+0.05 0.65+0.03* 0.46+0.03 0.62+0.05 0.67+0.06 0.49+0.05
ACUTE MALE CHRONIC MALE
Vehicle 1 Omg/kg 3 Omg/kg Vehicle 1 Omg/kg 3 Omg/kg
Urine volume 
(ml/lOOg) 
Osmolality 
(mOsm/kg) 
Sodium 
(nmol/min/lOOg)
4.9±0.7 
1541±66
9.1±0.7**
1012+101**
21.4±3.1**
388+71**
4.4+0.5
1880+165
5.6+0.4 
1790+94
6.8+0.8*
1413+128*
0.69±0.05 0.62+0.05 0.58+0.07 0.56+0.06 0.68+0.04 0.43+0.04
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Figure 3.8. BP in female normotensive rats after acute and chronic treatment with drug A.
SD rats were blood pressured by tail cuff plethysmography pre-treatment, and on days 1 
and 3 of treatment with drug A (■  =vehicle, A=drug A 1 Omg/kg).
Each point represents the mean±SEM of 6 separate determinations performed in triplicate.
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Table 3.4. Effect of orally administered drug A (10 mg/kg/day and 30mg/kg/day) on 
plasma parameters after 5 days of oral dosing in female and male SD.
Each point represents the mean±SEM of 6-8 separate determinations. *P<0.05, **P<0.01 
versus vehicle.
CHRONIC FEMALE CHRONIC MALE
Vehicle 1 Omg/kg 30mg/kg Vehicle 1 Omg/kg 3 Omg/kg
Plasma sodium 
(mmol/1) 136.8±0.2 136.8±0.2 144.7±7.1 134.3±0.5 133.1±0.8 131.3±3.3
Plasma osmolality 
(mOsm/kg) 297.2±0.9 295.4± 1.2 297.7±1.0 294.8±0.7 289.6±2.5 286.5±3.9
Plasma AVP 
(pmol/1) 5.4±0.4 5.6±0.5 7.1±0.4* 8.5±0.8 7.1±0.7 12.8±2.1**
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Figure 3.9. In vitro ViaR autoradiography after 5 days of oral drug A in female rat.
Figure 3.9. Effect of orally administered drug A at 0, 10 and 30mg/kg doses on the in vitro 
specific binding of I-labelled [d(CH2 )s, sarcosine ]AVP to kidney medullary ViaRs.
Results are expressed as percentage change from the binding seen with vehicle treated rats.
Each point represents the mean±SEM of 4 separate determinations performed in triplicate. 
*P<0.05, **P<0.01 versus vehicle.
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3.6 DISCUSSION
The results of this study demonstrate that, in vitro, drugs A-E act as competitive inhibitors 
of AVP at liver (order of potency A, E, C, D, B) and kidney ViaRs (order of potency A, E, 
C, B, D) and the kidney V2 RS (order of potency A, E, B, C, D). Drug A is the best 
competitive inhibitor of AVP at liver and kidney ViaRs and the kidney V2 RS. The IC50  
values calculated from the radioligand displacement curves indicate that drug A binds to 
the liver ViaR at approximately 17% of the affinity of AVP and has approximately 12.5% 
the affinity for the renal ViaR. At the kidney V2 R drug A has approximately 14% the 
affinity of AVP.
The in vivo time course and dose response studies show that oral drug A is an effective 
ViaR and V2 R antagonist. The inhibitory effect of drug A was dose- and time-dependent 
with maximal responses at lOmg/kg. In liver membranes the effect of drug A was not 
evident until 2 hours post gavage and its inhibitory effect lasted up to 4 hours. For the 
renal ViaR drug effect was seen after 1 hour and again lasted up until 4 hours post dosing, 
while for the renal V2 R, inhibitory effect was first seen after 2 hours and lasted up until 8 
hours post gavage. These results suggest that drug A is a good inhibitor of both Via and 
V2 RS in vitro and that the most suitable dosage regime would be two to three times daily.
From assessment of SBP in this study, 3 days of oral drug A did not cause a significant 
hypotensive effect in normal, hydrated, female rats while in vitro autoradiography 
confirmed blockade of the ViaRs by drug A. It is known, however, that blockade of the 
ViaR does not reduce BP in normal animals due to the buffering effects of an intact 
sympathetic nervous system and activation of the renin angiotensin system (385). Drug A 
was an effective V2 R antagonist to cause significant aquaretic responses with 5 days of
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oral treatment and these responses were different in both male and female rats. Acutely, 
male rats had a more pronounced aquaretic response than females at both 10 and 30mg/kg 
doses. After 5 days, however, the aquaretic response in both sexes was “blunted”. In 
females this reduction in urine output was less than that seen in male rats and aquaresis 
remained significant at both 10 and 30mg/kg doses. In the male rats, on the other hand, a 
significant aquaresis after 5 days was only seen with a dose of 30mg/kg.
A number of possible explanations exist for this turning down of the aquaretic response to 
AVP with chronic dosing of drug A. The most likely can be explained by the phenomenon 
known as tachyphylaxis. With some drugs the intensity of response to a given dose may 
change during the course of treatment. In these cases, responsiveness usually decreases as 
a consequence of continued drug administration to produce a state of relative tolerance to 
the drug’s effects. When responsiveness diminishes rapidly after administration of a drug 
the response is said to be subject to tachyphylaxis. While chronic blockade of the V2R 
using peptide receptor antagonists was not associated with persistent aquaresis (386), 
studies with non-peptide AVP receptor antagonists have, thus far, demonstrated no 
tachyphylactic effects. For instance, OPC 31260 had a sustained aquaretic effect in a 
coronary artery ligated rat model of heart failure (41) and YM087 remained a highly 
effective aquaretic agent after 7 days of treatment in female SD rats (46). Many different 
mechanisms may give rise to tachyphylaxis. They include: -
• Alteration in concentration of competing receptor ligands.
• Change in receptors.
• Change in signal pathways distal to the receptor.
• Increased metabolic degradation.
• Physiological adaptation.
Chapter 3: Characterisation o f  novel non-peptide AVP antagonists 111
In our study, the observed tachyphylaxis may conceivably result from an alteration in the 
AVP receptors and in particular receptor number. As can be seen in figure 3.3 there 
appears to be an up-regulation of all receptors by 24 hours post dosing and this increase in 
receptor number is significant for the renal V2 R, approximately 1.6 fold (P<0.01). It is 
conceivable that this “rebound” increase in the V2R may further increase with each day of 
dosing and with increased dosing frequency such that a higher and higher dose of oral 
antagonist is required to produce its desired effect, in this case an aquaresis. Another 
possible explanation is that after repeated dosing with a mixed AVP receptor antagonist 
AVP is increased as part of a feedback type response. This being the case then, once more, 
a higher concentration of drug A than that which is effective acutely would be required to 
produce any desired aquaretic response chronically. This explanation would also fit nicely 
with the fact that acutely, male rats demonstrate a greater diuresis than females but that 
over the 5 days of our study that response was reduced more significantly than the female 
chronic response. With greater initial aquaresis, and possibly dehydration, this would 
result in higher plasma AVP levels in the male animals. Our plasma AVP results do not 
directly compare acute with chronic dosing nor do they look at male plasma AVP acutely, 
however, at a dose of lOmg/kg/day, in both male and female rats, no significant increase in 
plasma AVP after 5 days, when compared to vehicle treated rats, was seen. On the other 
hand at a dose of 30mg/kg there is significance and more so in male rats (P<0.05; female 
and P<0.01; male). This would reflect a greater degree of dehydration in those animals 
given the highest drug dose once more as a result of a greater aquaresis in the males. 
Interestingly, in the initial time course study, plasma AVP was significantly decreased 
after 8 and 24 hours with a single 10 mg/kg dose of antagonist which is surprising in view 
of the above. This is unlikely to have been seen at a dose of 30mg/kg had this been
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included. In previous studies using the V2 R antagonists OPC 31260 (41) and YM087 (46), 
plasma AVP levels have been elevated after a single dose.
There was no significant rebound increase in V iaR number in both liver and kidney (figure 
3.3) and thus there is likely to be sufficient V iaR blockade throughout the study to avoid 
any systemic hypertensive effects.
Obviously other mechanisms for tachyphylaxis may be at work here, but an investigation 
into signal pathways, metabolic degradation and physiological adaptation were beyond the 
remit of this particular study.
In conclusion, these studies confirm that drug A is a potent, non-peptide, orally effective 
Via and V2R antagonist that has inhibitory effects on both the Via and V2 RS following oral 
dosing. After 5 days of dosing this effect is not well sustained and it may be that longer- 
term studies are required before this drug’s clinical usefulness can be properly assessed. If 
shown to be effective over the longer period it may prove useful in the management of 
CCF where increased AVP contributes to increased vascular resistance through its ViaR 
and to hyponatraemia via its effects at the V2 R to cause fluid retention.
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1. This study assessed the effects of combination therapy with the V ia receptor (ViaR) 
blocker OPC 21268 and angiotensin converting enzyme (ACE) inhibitor ramipril on 
systolic blood pressure (SBP), organ weights, metabolic and hormonal parameters in the 
adult spontaneously hypertensive rat (SHR).
2. The study was divided into 2 separate experiments: Study 1 and study 2. In the first, 
male SHR had telemetry probes inserted into their abdominal aortas at 16 weeks of age 
and, after recovery and an initial baseline SBP period of 5 days, were then randomised to 
receive ramipril (lmg/kg/day), OPC 21268 (6Omg/kg/day) or combination ramipril 
(lmg/kg/day) and OPC 21268 (60mg/kg/day) for 2 weeks with continuous SBP recording. 
In study 2, 16 week SHRs were randomised to the above 3 groups or vehicle and gavaged 
for 14 days. On days 10 and 11 these rats were placed in metabolic cages for 24 hour 
assessment of water and food intake as well as urinary parameters. After this 14 day 
period the rats were killed to assess cardiac mass, tissue enzyme inhibition, plasma 
biochemistry and plasma hormones.
3. Ramipril alone, or in combination, reduced SBP and relative left ventricular (LV) mass 
compared with OPC 21268 or vehicle treated animals (PO.Ol). Ramipril significantly 
inhibited renal and plasma ACE (P<0.01) and increased plasma renin activity (PRA). 
There was no significant effect on plasma arginine vasopressin (AVP) in ramipril, OPC 
21268 or combination treatment groups. OPC 21268 did not reduce SBP or LV mass 
despite significant V iaR blockade.
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4. This study demonstrates that in an adult rat hypertensive model, 2 weeks of V iaR 
antagonism is not additive or synergistic to ACE inhibition in terms of BP lowering or 
reduction of cardiac mass.
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4.2 INTRODUCTION
Hypertension is a common health problem within Western societies and is a major 
contributor to mortality and morbidity due to many cardiovascular diseases such as 
cerebrovascular accident, myocardial infarction and renal failure (1, 9). Increasingly the 
treatment thresholds for this condition are being lowered as it becomes clear that BPs 
previously considered “normal” are actually still high enough to contribute to 
cardiovascular risk. For instance a BP of 140/90, even without other cardiovascular risk 
factors, is now considered to be abnormal (9). In an attempt to reach these new “target” 
BPs increasing numbers of patients now require polypharmacy (387). A significant 
number of people remain hypertensive despite the current availability of a vast array of 
different numbers and groups of antihypertensive agents thus prompting the search for 
novel antihypertensive drugs (388).
AVP is a vasoactive peptide that mediates vasoconstrictor effects through AVP ViaRs in 
vascular smooth muscle and the brain, and its antidiuretic effects through the activation of 
V2  receptors (V2 RS) in the renal tubule. While it is clear that this nonapeptide has a role to 
play in the developmental stages of hypertension (50), its role in established hypertension 
as yet remains unclear. In rat models such as deoxycorticosterone acetate-salt (DOCA) 
hypertension, where AVP levels are elevated, this hormone has been shown to be 
important (120, 124). OPC 21268 or l-{l-[4-(3-acetylaminopropoxy)benzoyl]-4- 
piperidyl}-3,4-dihydro-2(lH)-quinolinone (Figure 4.1) is a non-peptide, orally active, 
selective AVP ViaR antagonist which has little effect at the AVP V2 R and is described in 
more detail in chapter 1 (section 1.4.1) (123). OPC 21268 has been shown to lower BP 
chronically in DOCA hypertension (124), in Dahl salt sensitive (DSS) hypertension (389, 
390) and also in the malignant phase of hypertension in the stroke-prone SHR (391).
Chapter 4: Combination ViaR antaeonism and ACE inhibition in SHR 118
Through chronic administration of this drug it is now clear that AVP does not reverse 
adrenocorticotrophin-induced hypertension in the Sprague-Dawley rat (268) and is not 
involved in renovascular hypertension (267). In male DSS rats it has been shown that the 
combination of OPC 21268 and ACE inhibitor captopril was not additive in terms of BP 
reduction, although each individual treatment attenuated hypertension (389). However, a 1 
week period of V iaR antagonist OPC 21268, in adult SHR, failed to result in any BP 
lowering effects (50).
As compared to that of AVP, the role of the renin angiotensin system (RAS) in the 
regulation of BP and in cardiovascular diseases has been well characterised (392-394). 
ACE inhibitors are highly efficacious BP lowering agents in animals and humans and are 
widely used in the treatment of hypertension, both alone and in combination with other 
agents (1). They are currently the ‘gold standard’ drug group used in the management of 
diabetic nephropathy (286, 395) and cardiac failure (396). No studies thus far have looked 
at combination therapy of ACE inhibition with V iAR antagonism in the adult hypertensive 
rat to assess whether, at this mature stage, any additive BP lowering benefits exist.
The aims of this study were to examine the BP effects of 2 weeks of treatment with ACE 
inhibition and V iAR antagonism in adult SHR and to look for any additive benefits in 
terms of SBP, plasma and metabolic parameters and organ weights with this combination 
therapy.
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Figure 4.1. Representation of the chemical structure of OPC 21268. Modified from 
(397).
4.3 EXPERIMENTAL PROTOCOL
4.3.1 Ethics
This experiment was approved by the Austin and Repatriation Medical Centre Ethics 
Committee and performed according to the National Health and Medical Research Council 
of Australia guidelines for animal experimentation.
4.3.2 Drugs
OPC 21268 was a generous gift from the Otsuka Pharmaceutical Co. Ltd (Tokushima, 
Japan). Ramipril was purchased from Aventis Pharmaceuticals (New Jersey, USA). OPC 
21268 was suspended in 0.5% methylcellulose (BDH Pharmaceuticals, Poole, UK) while 
ramipril was dissolved in water. Both of these drugs were administered orally by gavage.
4.3.3 Study 1
16 week male SHR had telemetry probes inserted (n=13), as described in chapter 2 (section 
5.5.2). After a 7 day surgical recovery period, baseline 24 hour SBPs were recorded for a
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further 5 days after which time the animals were randomised to the following treatment 
groups - OPC 21268 (n=5), ramipril (n=4) and ramipril plus OPC 21268 (n=4). Drugs 
were administered by gavage and dosing continued for 14 days. OPC 21268 was given 
twice daily at a dose of 30mg/kg with ramipril being given once daily at a dose of 1 mg/kg. 
SBPs were sampled every 30 minutes for 30 seconds for the duration of this study. All 
stored BP data was gathered retrospectively from the telemetry computer and SBPs from 
each 8am-8am 24 hour period averaged. Excluded from subsequent analysis was any SBP 
of greater that 220 mmHg or less than 80 mmHg as they were presumed artefactual. For 
each treatment group the blood pressures for treatment days 1-14 were averaged and 
analysed as compared to the average overall baseline blood pressure. In addition, for each 
individual SHR, the daily drop in SBP relative to that animals average baseline pressure 
was calculated.
4.3.4 Study 2
16 week SHR’s without telemetric probes in situ were randomised to receive vehicle, OPC 
21268 (30mg/kg bd), ramipril (lmg/kg/day) or ramipril plus OPC 21268 (n=6/group). On 
days 10 and 11 of treatment, animals were placed into metabolic cages to assess 24 hour 
food and water intake, urine output and urinary sodium and osmolality (n=6/group). Rats 
were killed by decapitation on day 14, 1 hour post gavage, and trunk blood collected for 
the measurement of plasma sodium and osmolality, plasma AVP concentration and plasma 
ACE and PRA (n=6/group) as described in chapter 2 (section 2.6.7). Kidneys were 
collected, weighed and rapidly frozen in dry ice chilled isopentane for in vitro 
autoradiography (n=6/group) as described in chapter 2 (sections 2.6.2.1 and 2.6.2.3). Liver 
was removed and membranes prepared immediately and stored in liquid nitrogen prior to
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V iaR binding studies (n=6/group) as described in chapter 2 (section 2.6.4). Heart was 
removed and dissected into left and right ventricles and weighed (n=6/group).
4.4 STATISTICAL ANALYSIS
Data were analysed by analysis of variance (ANOVA) with or without repeated measures 
using the Statview SE=Graphics programme (Brainpower, Calabasas, CA). Comparisons 
of group means were performed by Fisher’s least significant difference method. Data are 
shown as means±SEM unless otherwise specified. P<0.05 was viewed as statistically 
significant.
4.5 RESULTS
4.5.1 Study 1
4.5.1.1 SBP
The average baseline SBP over 5 days was 162±4 mmHg (n=13). The mean baselines for 
each group being: 160.8±4.8 (OPC 21268), 165.7±10.0 (ramipril) and 160.2±5.5
(ramipril+OPC 21268) (n=4-5/group). There was no statistical difference between groups.
Day 1-14 average SBPs per group were: 162.9±5.1mmHg (OPC 21268),
145.7±9.7mmHg (ramipril) and 147.5±6.2mmHg (ramipril + OPC 21268). When 
compared to the average baseline of 162±4 mmHg, OPC 21268 was not statistically 
different while with ramipril alone, PO.Ol, and ramipril plus OPC 21268, P<0.05. The 
difference in treatment BPs between ramipril alone and ramipril+OPC 21268 did not reach 
significance (Figure 4.2.).
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The average changes in SBP per treatment group, as compared to that group’s own average 
baseline BP were (day 14 data only given): +4.7±4.2mmHg (OPC 21268),
-22.3±6.7mmHg (ramipril) and -12.9+1.3mmHg (ramipril+OPC 21268). Again at day 14 
the change in SBP with OPC 21268 was not statistically different as compared to baseline 
data while ramipril and ramipril+OPC 21268 did reach significance (P<0.01 and P<0.05 
respectively). The difference in treatment BPs between ramipril alone and ramipril+OPC 
21268 did not reach significance (Figure 4.2).
4.5.2 Study 2
4.5.2.1 Metabolic studies
Food and water intake, urinary volume, sodium and osmolality were not significantly 
altered by any of the treatments. Body weight, likewise, was similar across all groups 
(Table 4.1).
4.5.2.2 Relative organ weights
As expected ramipril alone, or in combination with OPC 21268, significantly reduced heart 
and LV mass (PO.Ol). OPC 21268 alone had no effect on total heart or LV mass. 
Combination treatment with ramipril and OPC 21268 showed no additional organ weight 
reduction over and above that seen with ramipril alone. Relative right ventricular (RV) 
and kidney weights were unaltered by any treatment (Figure 4.3).
4.5.2.3 Plasma data
Plasma osmolality and AVP were unaltered by any treatment. As expected ramipril 
therapy resulted in a significant inhibition of plasma ACE activity (P<0.01) and a 
significant increase in PRA (PO.Ol) (Figure 4.4).
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4.5.2.4 In vitro ACE autoradiography and liver ViaR binding studies
ACE autoradiography confirmed the inhibition of renal tissue ACE by ramipril (Figure 
4.5). Liver V iaR binding studies confirmed the inhibition of the V iaR by OPC 21268 
(Figure 4.5).
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Figure 4.2. SBP telemetry data
A. The average baseline SBP’s per group as well as those for days 1, 3, 5, 7, 10, 12 and 14 
of drug treatment. Each bar represents the mean±SEM of 4-5 separate determinations. 
P<0.01 for drug treatment ramipril alone (compared to baseline). P<0.05 for drug 
treatment ramipril+OPC 21268 (compared to baseline).
B. Telemetry data expressed as a fall in SBP over baseline for each individual animal 
where each point represents the mean±SEM of 4-5 separate determinations. P<0.01 for 
drug treatment ramipril alone. P<0.05 for drug treatment ramipril+OPC 21268.
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Table 4.1. Body weight and results from metabolic studies to assess differences in food, 
water consumption and renal parameters on days 10 and 11 between the 4 treatment groups 
shown, n=6/group. No statistical differences were seen.
Treatment groups
Param eter Vehicle OPC 21268 Ramipril Ramipril! 
OPC 21268
Body weight (g) 353±4 351±10 35014 340110
Food consumption
(g/100g)
5.8±0.4 5.8±0.2 6.010.4 6.210.4
Water
consumption
(ml/lOOg)
34.0±12.7 35.2±13.9 40.0114.6 35.9113.1
Urine volume 
(ml/lOOg)
3.1±0.4 3.110.2 3.510.3 3.810.3
Urine sodium 
(pmol/min/lOOg)
3.1±1.6 3.511.1 2.610.9 2.210.8
Urine osmolality 
(mOsm/kg)
2022±316 2175190 19641140 20461137
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Figure 4.3. Body weight and relative organ weights per treatment group
Body weight and relative organ weight for each treatment group as given above.
Each point represents the mean±SEM of 6 separate determinations. **P<0.01 versus 
vehicle treated hypertensive controls. BW=body weight.
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Vehicle OPC Ramipril Ramipril+ Vehicle OPC Ramipril Ramipril-*'
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Figure 4.4. Plasma data per treatment group 
Plasma data for each treatment group shown above.
Each point represents the mean±SEM of 4 separate determinations performed in duplicate. 
**P<0.01 versus vehicle-treated hypertensive controls.
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Figure 4.5. Renal ACE in vitro autoradiography and liver ViaR binding studies to 
validate treatment efficacy
Renal ACE in vitro autoradiography and liver ViaR binding studies demonstrating tissue 
ACE inhibition by ramipril and ViaR inhibition by OPC 21268 respectively.
Each point represents the mean±SEM of 5-6 separate determinations performed. *P<0.05 
and **P<0.01 versus vehicle treated hypertensive controls.
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4.6 DISCUSSION
The role of ang II in hypertension as a potent vasoconstrictor, antinatriuretic and trophic 
hormone is well characterised (392-394). Much less is certain as regards AVP. This study 
looked at BP effects of combination therapy with an ACE inhibitor and V iaR antagonist in 
adult SHR and demonstrated that V iaR antagonism alone did not lower BP. ACE 
inhibition and combination ACE inhibition with V iaR antagonism did result in BP 
lowering but there were no additive or synergistic effects with the addition of V iaR 
blockade. Likewise, heart and LV weights were reduced with ACE inhibition but not 
V iaR blockade alone and no additional benefits were seen with combination treatment. 
The lack of effect of OPC 21268 was not due to any failure to block the V iaR since 
binding studies clearly demonstrate V iaR inhibition. It appears therefore that AVP does 
not have a major role to play in the maintenance of BP in the adult SHR and has no role to 
play as add on therapy to ACE inhibition in this particular model of essential hypertension.
As stated in the introduction, our group has previously reported that the V iaR antagonist, 
OPC 21268, delayed the progression of hypertension in the young SHR in a similar 
manner to ACE inhibitors (50). No additive effects of V iaR antagonism and ACE 
inhibition given during this developmental stage were observed. These results suggested 
that AVP, via V iaRs and angiotensin II, are involved in the pathogenesis of hypertension 
and may act via a common mechanism in male SHRs in the developmental stage. While it 
is clear that AVP antagonism has no role to play over and above ACE inhibition in the 
developmental phases of hypertension, its role in established hypertension as yet remains 
unclear. In rat models such as DOCA (124) and DSS hypertension (389, 390), where 
plasma AVP levels are elevated, then this hormone has been shown to play a role and 
V iAR blockade is therefore beneficial here. In models of essential hypertension, where
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plasma AVP is not classically elevated, there have been reports that AVP receptor 
blockade lowers BP as well as reports to the contrary (385, 398) while, as stated in the 
introduction, a 1 week study conducted by our group could demonstrate no BP lowering 
effect of OPC 21268 alone on male adult SHR (50). To date, nobody has looked at the 
combined effects of ViaR with ACE antagonism in this animal model.
The mechanisms and sites of interaction of the AVP and RASs are not clearly understood 
at this time and few data are available concerning the possible interaction between 
angiotensin II and AVP. Klingbeil et al rnfused AVP and angiotensin II alone and in 
combination to determine whether a synergism could be found between these two peptides 
in the release of adrenocorticotropic hormone (399). Cowley et al infused AVP alone, or 
in combination with angiotensin II, to determine whether combined hormone 
administration did enhance each hormone’s singular hypertensive action (400). These 
authors found that the effects of the combination of hormones were not enhanced 
compared with the response to the individual hormone infusions, thus providing parallels 
with the results of this present study. Zhang et al demonstrated a reduction in AVP levels 
with captopril treatment (401) while Okuno et al have shown that intraventricular and 
intravenous captopril infusions in SHR did not alter either central or peripheral AVP levels 
(402). This latter study concurs with our findings where AVP levels were unaltered by any 
of the treatments. This would indicate that these 2 hormonal systems work independently 
of each other in terms of BP control. At the receptor level, desensitisation of the ViaR is 
thought to be fast and accompanied by the sequestration of receptors inside the cell within 
both tissues and transfected cells (403). Thus the ViaR undergoes both homologous and 
heterologous desensitisation, the latter being triggered by angiotensin II. This 
phenomenum of hormone-stimulated sequestration has been demonstrated in vascular
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smooth muscle cells that express both receptor types (404, 405). In the context of ACE 
inhibition where angiotensin II levels are lower, up-regulation of AVP V iaR cell surface 
numbers and thus a greater response to AVP receptor antagonism might be expected. No 
additive BP lowering effects of ACE inhibition and V iaR antagonism was demonstrated 
here and therefore, in the adult SHR, any such up-regulation doesn’t seem to play a role. 
As well as their peripheral actions, angiotensin II and AVP also act centrally, through the 
circumventricular organs, to influence cardiovascular regulation. The area postrema, a 
circumventricular organ in the brainstem, mediates at least some of the central actions of 
these peptides. AVP appears to act in the area postrema to cause sympathoinhibition (406) 
and a shift in baroreflex control of the sympathetic nervous system to lower pressures. In 
contrast to AVP ang II has effects in the area postrema to blunt baroreflex control of heart 
rate and cause sympathoexcitation (406) and so, centrally, both hormones have opposing 
actions and it may be that in this hypertensive model central sympathoinhibitory influences 
and peripheral vasoconstriction are in balance with each other.
After 14 days of treatment only the animals receiving ramipril showed any reduction in 
relative cardiac organ weights. As described in chapter 1, both ACE inhibitors and V iAR 
antagonists have antimitogenic actions and it may be that a more prolonged period of V iaR 
antagonism is required before these structural benefits play a more important role and 
ultimately lower BP.
The above contrasts to the findings of a pilot study in diabetic SHR. This was undertaken 
in adult diabetic SHR on chronic perindopril treatment made available to us with telemetry 
probes in situ. Here, by introducing another disease into the equation, and one in particular 
that is associated with reduced PRA and elevated plasma AVP levels, a reduction in BP
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with OPC 21268 was shown and this appeared to be additive to that seen with perindopril. 
In diabetes mellitus (DM) AVP is known to be elevated, along with its V iaR, at least in the 
earlier stages of this disease. The AVP system in DM is “out of balance” therefore and 
may be contributing towards hypertension, a situation not seen in the non-diabetic SHR. 
Blockade of this up-regulated V iaR system in DM will therefore result in a lowering of 
BP. This pilot study and its results will be described in more detail in chapter 5.
The contribution of AVP to the maintenance and development of human hypertension is 
not well understood at this time and published data on the effect of non-peptide AVP 
receptor antagonists in human BP control has thus far been limited. Results regarding 
plasma AVP levels in hypertensive patients are not consistent, with high levels in some 
studies but normal or low levels in others (269-271). There does, however, appear to be a 
subset of hypertensive patients, those with associated low plasma renin levels, in whom 
AVP is consistently elevated. These patients include the elderly, African-Americans, as 
well as patients with chronic renal failure and DM (27, 29, 272, 273). These studies are 
discussed in more detail in chapter 1 (section 1.5.1.2).
In conclusion, this study demonstrates that in an adult rat model of hypertension, the 
combination of ACE inhibitor and V iaR antagonist, for 2 weeks, is not additive or 
synergistic in terms of BP lowering or heart weight reduction and V iaR antagonism alone 
had no hypotensive or organ weight effects in this model. It seems unlikely therefore that 
combination therapy has a role to play in blood pressure lowering and certainly in those 
members of the population with normal plasma renin levels.
Chapter 5
Regulation of the vasopressin ViA receptor in 
experimental diabetes mellitus and hypertension
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5.1 SUMMARY
1. The aim of the following studies was to look at the effects on vasopressin (AVP) and 
the AVP V ia receptor (ViaR) system of 8 weeks of streptozotocin (STZ-) induced diabetes 
mellitus (DM) in male spontaneously hypertensive rat (SHR).
2. Male SHR (n=16) were made diabetic at 8 weeks of age, given daily subcutaneous 
injections of 4 units of long acting protophane insulin, weighed weekly and underwent 
fortnightly blood glucose measurements (DM-SHR). Male SHR (n=8) were given citrate 
buffer at 8 weeks of age and served as control animals (SHR). In weeks 4 and 8 systolic 
blood pressure (SBP) was assessed by tail cuff plethysmography and in week 8 rats were 
placed in metabolic cages for the measurement of food and water consumption as well as 
urine output (n=l 1 DM-SHR; n=8 SHR). The urine was subsequently analysed for urinary 
albumin excretion by radioimmunoassay. The rats were killed at the end of week 8 and 
plasma collected for the measurement of Haemoglobin A le (HBAlc), glucose and AVP. 
Pieces of liver and kidney were snap frozen for real time PCR and fresh liver and kidney 
membranes prepared for subsequent kinetic binding studies using the ViaR selective 
radioligand 125I[d(CH2 )s, sarcosine7]-AVP.
3. After 4 and 8 weeks of DM, SBP was reduced in DM-SHR compared to SHR. (4
weeks: 180±4 mmHg versus 193±4 mmHg; P<0.01; 8 weeks: 186±4 mmHg versus
213±4 mmHg; P<0.01). Urinary albumin excretion rate in week 8 was significantly
increased in DM-SHR (1.77x/-^1.1815 mg/24 hours) as compared to SHR (0.67xA-1.21
mg/24 hours; PO.Ol) while plasma AVP was significantly elevated in DM-SHR 
(11.2±0.7pmol/l) versus SHR (9.2±0.4pmol/l); P<0.05). mRNA for both liver and kidney
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V iaR were unchanged from DM-SHR to SHR while, at the protein level, Scatchard 
analysis demonstrated up-regulation of both liver and kidney ViaR density (Bmax) in DM- 
SHR (Liver: 96.1±7.6 fmol/mg versus 66.7±8.2 ftnol/mg; P<0.05; Kidney: 11.0±1.1 
finol/mg versus 8.04±0.61 fmol/mg; P<0.05)). No change in receptor affinity (Kd) was 
seen.
4. In this study up-regulation of liver and kidney V iaRs occurs in the setting of stable 
AVP gene transcription. These results suggest that changes in receptor processing may be 
responsible for the differential regulation of AVP receptors that occurs in the 8 week 
diabetic, hypertensive rat. This study is the first to show that in a rat model combining DM 
and hypertension there is both an increase in plasma AVP and up-regulation of the V iaR in 
liver and kidney. As AVP is thought to contribute to the renal damage seen in diabetic 
nephropathy then this study provides a rationale for the use of V iaR antagonists in this 
disease.
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5.2 INTRODUCTION
DM causes hypertonicity, polyuria and polydipsia and, long term, is almost always 
associated with complications of the cardiovascular system such as vascular disease, renal 
disease and hypertension (289, 407-409). AVP is central to control of fluid balance and 
blood pressure (BP) (385). Plasma AVP levels are elevated in a number of disease states 
that include DM (23, 51, 125) and hypertension (120). Increased AVP may have adverse 
actions by increasing peripheral resistance via constrictor actions at the ViaR and 
contributing to fluid retention and hyponatraemia through effects on the renal V2 R. In 
addition, AVP can act as a mitogen and in a manner analogous to angiotensin II may have 
deleterious effects when present long-term and in excess (30, 31). Hyperglycaemia itself 
initially promotes mesangial cell proliferation and extracellular matrix production but 
through time will inhibit them (410). Diabetic nephropathy has a high associated 
morbidity and mortality. It is characterised by a number of pathological changes not least 
of which are that of excessive extracellular matrix production, cell proliferation and 
contraction (286). Previous studies have looked at the regulation of AVP and its receptors 
in DM but these have tended to be short-term or inconclusive. For instance previous 
experiments revealed that in normotensive, Sprague Dawley (SD) rats with 2 weeks of 
STZ-DM, elevated plasma AVP levels were associated with a reduction of renal and 
hepatic ViaRs. In addition to producing a reduction in second messenger activation, 
down-regulation of the ViaR was shown to contribute to diminished ViAR-mediated 
biological responses to AVP (51) and was paralleled by a reduction in receptor mRNA 
levels (125). The pathophysiological significance of reduced renal and hepatic ViaRs in 
normotensive DM rats with little or no renal pathology is at this stage unclear. A recent 
study in the 10 week genetically diabetic (db/db) mouse, a model for type II DM, 
demonstrated significant down-regulation of hepatic ViaR mRNA and protein in the liver
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of the db/db mouse (322). Renal V iaR regulation was however not assessed in this study. 
Thus with such limited information currently available on the regulation of the V iaR 
system in STZ-DM it is important to clarify the role of AVP and its receptors in DM, and 
in particular the V iaR, prior to performing intervention studies with the now available non­
peptide AVP receptor antagonists.
The general aim of this study was to assess the regulation of AVP and its V iaR both at a 
mRNA and protein level in a rat model combining hypertensive with long-term STZ-DM.
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5.3.1 Ethics
This experiment was approved by the Austin and Repatriation Medical Centre Ethiics 
Committee and performed according to the National Health and Medical Research Council 
of Australia guidelines for animal experimentation.
5.3.2 Drugs
OPC 21268 was a generous gift from Otsuka Pharmaceutical Co. Ltd (Tokushima, Japan). 
Perindopril was purchased from Aventis Pharmaceuticals (New Jersey, USA). OPC 21268 
was suspended in 0.5% methylcellulose (BDH Pharmaceuticals, Poole, UK) while 
perindopril was dissolved in water. Both of these drugs were administered orally by 
gavage.
5.3.3 Study 1
5.3.3.1 AVP ViaR system regulation in the SHR after 8 weeks STZ-DM
To induce DM, male SHR (age 8 weeks) received tail vein injections of STZ (45mg/kg). 
Control rats received an equivalent volume of citrate buffer as described in chapter 2 
(section 2.2.2). Rats were weighed weekly and diabetes monitored by fortnightly blood 
glucose determination. Any animal with a blood sugar of less than 17mmol/l at any stage 
was excluded from the study. The diabetic rats received 4 Units of long acting protophane 
insulin subcutaneously daily via a Novo Pen 3 (Novo Nordisk Pharmaceuticals Pty. Ltd). 
During the fourth and eighth week of DM SBP was determined using tail cuff 
plethysmography and during the eighth week of DM rats were housed in metabolic cages
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for the measurement of food and water intake and renal parameters. After 8 weeks rats 
were killed (n=8 SHR and n = ll DM-SHR) and trunk blood collected for the measurement 
of plasma AVP, angiotensin converting enzyme (ACE), plasma renin activity (PRA), 
sodium, osmolality and HBAlc. Livers and kidneys were removed and fresh membranes 
prepared for receptor binding studies as described in sections 2.6.3, 2.6.4 and 2.6.5. Small 
cross sections of kidney and pieces of liver were removed and snap frozen in dry-ice 
chilled isopentane for real time PCR as described in section 2.7.1.
5.3.4 Study 2
5.3.4.1 AVP ViaR regulation in the SHR after 8 months STZ-DM
A separate study was undertaken by a collaborating group in which SHR were made 
diabetic for 8 months. Fresh livers and snap frozen kidneys were made available to allow 
us a preliminary look at AVP and V iaR regulation at this 8 month time point. From liver, 
fresh membranes were prepared for Scatchard analyses and the frozen kidneys used for in 
vitro ViaR autoradiography as described in chapter 2 (sections 2.6.2 and 2.6.5.3).
5.3.5 Study 3
5.3.5.1 SBP in DM-SHR with ACE inhibition and ViaR antagonism
A short pilot study was also undertaken in male DM-SHR made available from another 
study. These animals had telemetric probes in situ and were approximately 24 weeks of 
age. All had been diabetic since age 8 weeks (n=6). Half of the animals had been 
receiving perindopril therapy for the preceding 10 week period and that was on going 
(n=3), while the others had received no prior drug treatment (n=3). Baseline BPs were
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monitored for 4 days, OPC 21268 (30mg/kg bd) given for 3 consecutive days followed by 
a 10 day “drug wash out period” during which time perindopril therapy continued. 24 hour 
SBP was monitored continuously throughout.
5.4 STATISTICAL ANALYSIS
Data were analysed by analysis of variance (ANOVA) with or without repeated measures 
using the Statview SE=Graphics programme (Brainpower, Calabasas,CA). Comparisons 
of group means were performed by Fisher’s least significant difference method. 
Albuminuria data was logarithmically transformed before statistical analysis. Data are 
shown as means±SEM unless otherwise specified. P<0.05 was viewed as statistically 
significant.
5.5 RESULTS
5.5.1 Study 1
5.5.1.1 Characterisation of the diabetic model 
Body weight
Of the 16 SHR initially injected with STZ, 11 were available by week 8; 2 rats having been 
excluded when their random blood sugars were persistently below 17mmol/l and the other 
3 having died at various time points throughout.
All animals gained weight over the 8 week study period (P<0.01) but compared to control 
SHR, the DM-SHR gained significantly less weight (P<0.01)(Figure 5.1).
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Blood pressure
Mean SBP was significantly higher in SHR compared to DM-SHR at both 4 and 8 weeks 
(4 weeks: 193±4 mmHg versus 180±4 mmHg; PcO.Ol; 8 weeks: 213±4 mmHg versus 
186±4 mmHg; PcO.Ol) (Figure 5.2).
Metabolic parameters
Diabetic rats ate more, drank significantly more water (PcO.Ol) and passed significantly 
more urine (PcO.Ol) compared to control SHR. Urinary albumin excretion was likewise 
elevated when compared to control rats (PcO.Ol)(Figure 5.3). Urinary osmolality was 
significantly lower (PcO.Ol) whilst urinary sodium significantly higher in the diabetic 
animals (PcO.Ol)) (Figure 5.3).
Biochemical parameters
HBAlc and plasma glucose were significantly elevated in the diabetic animals compared 
to their controls (PcO.Ol) (Figure 5.4). Plasma osmolality was significantly elevated 
(PcO.Ol) while plasma sodium significantly reduced (PcO.Ol) in DM-SHR compared to 
SHR (Figure 5.4).
Hormonal parameters
Plasma AVP (Pc0.05) and ACE (PcO.Ol) were significantly elevated in DM-SHR as 
compared to SHR. No statistical differences were found in PRA (Figure 5.5).
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Organ weights
There was no statistical difference in relative heart weight between diabetic and control 
SHR after 8 weeks (Figure 5.6).
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Liver and kidney weights were both significantly increased in the diabetic group. (PcO.Ol) 
(Figure 5.6). Mesenteric weights were no different (Figure 5.6).
5.5.1.2 Hepatic and renal Vi aR mRNA
No alteration in the quantity of hepatic or renal V iaR mRNA was found between DM-SHR 
and SHR (Figure 5.7).
5.5.1.3 Hepatic and renal V iaR regulation
Using Scatchard analysis, renal V iaR number (Bmax) was significantly increased by 
approximately 20% (Pc0.05) in DM while receptor affinity (Kd) was unchanged. 
Likewise hepatic ViaR number was found to be higher by approximately 50% in the DM- 
SHR (Pc0.05) but the affinity for AVP did not alter (Figure 5.8).
5.5.2 Study 2
After 8 months of DM plasma AVP was not significantly elevated in DM-SHR as 
compared to control SHR at this time point (DM-SHR; 8.29±0.4pmol/l, n=18 versus SHR; 
7.20±0.4pmol/l, n= ll). Scatchard analysis performed on liver membranes could 
demonstrate no differences in Bmax or Kd between the 2 groups (Figure 5.9). In vitro 
autoradiography on kidney, although able to give less information than Scatchard analysis, 
did reveal a down-regulation in receptor density after 8 months of combined DM and 
hypertension although this did not reach significance (Figure 5.9).
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5.5.3 Study 3
SBP is expressed as mean 24 hour BP in figure 5.10. In DM-SHR treated with OPC 21268 
alone, a 2-4% fall in SBP over the treatment period was seen. This lowering of BP 
appeared to persist and if anything was slightly increased for a number of days after 
cessation of therapy then the mean 24 hour SBP gradually climbed back to baseline levels 
by day 14 (n=3). In the DM-SHR, treated with chronic ACE inhibition, the addition of 
V iaR blockade for 3 days gave an approximate 6% fall in mean BP and this also slowly 
returned to baseline levels over the next 10 days (n=3).
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Figure 5.1. Weekly animal weight versus time in SHR((H) versus DM-SHR(A).
Each bar represents the mean±SEM of 8 separate determinations for SHR and 11 separate 
determinations for DM-SHR. **P<0.01 (between group comparison in week 8). 
++P<0.01 (intragroup comparison; week 8 as compared to baseline).
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Figure 5.2. SBPs as measured by tail cuff plethysmography in SHR( A ) and DM-SHR( ) 
in study weeks 4 and 8.
Each point represents the mean±SEM of 8 separate determinations for SHR and 11 
separate determinations for DM-SHR. **P<0.01 (between group comparison in week 8). 
++P<0.01 (intragroup comparison; week 8 as compared to baseline).
Chapter 5: Regulation o f the AVP ViaR in experimental DM and hypertension 147
300-
200 -
1 oo-
Water consumption (g/100g) 
* *
25 -
20 -
15-
10 -
5 -
0-
Urinary volume (ml/100g) 
* *
Urinary sodium (pmol/min/100g)
1.25 -
0 .50 -
0 .25 -
Food consumption (g/100g)
* *
-150
-100
Urinary osmolality (mOsm/kg) -3000
■2000
1000
Urinary albumin excretion (mg/24h)
* *
Figure 5.3. Parameters derived from metabolic caging of SHR (open bars) and DM-SHR 
(closed bars) in week 8 of DM.
For urinary albumin excretion each bar represents the mean x/-^SEM of 8 separate 
determinations for SHR and 11 separate determinations for DM-SHR. All other bars 
represent the mean±SEM of 8 separate determinations for SHR and 11 separate 
determinations for DM-SHR. **P<0.01.
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Figure 5.4. HBAlc, plasma glucose, osmolality and sodium in SHR (open bars) versus 
DM-SHR (closed bars) after 8 weeks of STZ-DM.
Each bar represents the mean±SEM of 8 separate determinations for SHR and 11 separate 
determinations for DM-SHR. **P<0.01.
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Figure 5.5. Hormonal parameters in SHR (open bars) versus DM-SHR (closed bars) after 
8 weeks of STZ-DM.
Each bar represents the mean±SEM of 8 separate determinations for SHR and 11 separate 
determinations for DM-SHR. **P<0.01.
Chapter 5: Regulation o f the AVP ViaR  in experimental DM and hypertension 150
Heart weight/BW (g/kg) Left ventricle/BW (g/kg)
0 .75 -
0 .50 -
0 .25 -
0.00
Right ventricle/BW (g/kg) Liver/BW (g/kg)
Kidney/BW(g/kg) 
**
Mesenteric/BW (g/kg)
Figure 5.6. Relative organ weights in SHR versus DM-SHR after 8 weeks of STZ-DM.
Each bar represents the mean±SEM of 8 separate determinations for SHR and 11 separate 
determinations for DM-SHR. * *P<0.01.
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Figure 5.7. Regulation of Vi aR mRNA
Regulation of V iaR mRNA in A. Liver and B. Kidney in SHR (open bars) versus DM- 
SHR (closed bars). Each bar represents the mean±SEM of 5 separate determinations for 
both SHR and DM-SHR.
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Figure 5.8. Hepatic and renal Bmax and Kd in SHR and DM-SHR at the ViaR after 8 
weeks of STZ-DM
A, Summary table showing hepatic and renal Bmax and Kd in SHR and DM-SHR for the 
V iaR after 8 weeks STZ-DM. B. Representative hepatic V iaR Scatchard analyses from
both SHR (A ) and DM-SHR ( ). C. Representative renal V iaR Scatchard analysis from 
both SHR (A ) and DM-SHR ( ).
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GROUP SHR
(n=8)
DIABETIC SHR 
(n=8)
P VALUE
LiverViA Bmax
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Figure 5.9. Hepatic Bmax and Kd in SHR and DM-SHR at the V iaR after 8 months of 
STZ-DM
A. Summary table showing liver Bmax and Kd in SHR (A ) and DM-SHR( ) for the ViaR 
after 8 months STZ|-DM. B. Representative liver ViaR Scatchard analysis from both 
SHR (A ) and DM-SHR ( ). C. ViaR in vitro autoradiography in kidney sections from
SHR (open bars) and DM-SHR (closed bars). Results are expressed as mean±SEM of 6-8 
separate determinations and expressed as % change in binding as compared to SHR.
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Figure 5.10. Representation of BP changes in untreated DM-SHR given OPC 21268 
versus DM-SHR given OPC 21268 and perindopril
Change in average 24 hour SBPs relative to a 4 day pre-treatment baseline in A. Untreated 
DM-SHR given OPC 21268 for 3 days ( ) and B. DM-SHR given OPC 21268 for 3 days
on a background of ongoing chronic perindopril therapy (A). Each point represents the 
mean±SEM of 3 separate determinations.
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5.6 DISCUSSION
The regulation of AVP and its receptors in DM has thus far been little researched. This 8 
week diabetic study confirms previous findings of elevated plasma AVP concentrations in 
insulin-deficient DM and interestingly it demonstrates for the first time up-regulation of 
hepatic and renal V iaR numbers in a long-term and hypertensive model of this disease. 
The results of this study also show that changes in AVP receptor numbers were not 
accompanied by concomitant changes in liver or kidney V iaR mRNA.
Characterisation of this 8 week, STZ-induced model of DM was largely as expected when 
compared to that found previously by other groups. Weight gain is significantly less in the 
diabetic group as compared to control while HBAlc and plasma glucose are elevated to 
predictable values. Plasmas AVP and ACE are higher in DM-SHR as compared to control, 
while PRA remains unaltered. It is well known that AVP, in a bid to combat excessive 
dehydration, is raised in the diabetic state. Likewise, it has been shown that serum ACE is 
higher in the diabetic compared to control animal (411) and that this tends to be inversely 
proportional to the degree of diabetic control (412). PRA levels in DM appear to be more 
variable. A previous study within our group demonstrated no change in plasma PRA (413) 
while others have found this hormone to be reduced (411). In this study, PRA levels 
tended to be higher in the DM-SHR as compared to SHR although this was not statistically 
significant. This may reflect a slightly higher degree of dehydration within these diabetic 
animals as metabolic studies revealed the DM-SHR to be sodium excretors as compared to 
the more common finding of urinary sodium retention (375). Plasma osmolality is 
significantly higher in the DM-SHR as compared to SHR. The lower plasma sodium in the 
diabetics reflects this high osmolality as the concentrations of plasma solutes such as
Chapter 5: Regulation o f the AVP ViaR in experimental DM and hypertension 156
glucose and triglycerides seen in this disease give rise to a state of pseudohyponatraemia. 
All other aspects of the metabolic study were as would be expected in that the DM-SHR 
drank more, ate more and passed more urine of a lower osmolality than their non-diabetic 
counterparts. In terms of SBP, the development of hypertension was not as great in DM- 
SHR compared with controls. This finding agrees with that of previous studies (414). In 
terms of organ weights, these were adjusted for body weight in order to account for 
diabetic growth retardation. With this taken into account cardiac weights were not 
significantly different between the 2 groups. In view of the finding that SBP in the DM- 
SHR was significantly lower than in controls it may be that after adjustment for this 
variable then DM per se may cause cardiac hypertrophy, but this was not undertaken here. 
Indeed, Black et al looked at the hearts from diabetic SHR, 12 weeks post induction of 
STZ-DM, and found significant increases in cardiac sizes at this time point despite there 
being lower BPs in this group (414). As expected kidney and liver sizes were significantly 
greater in the DM-SHR compared to SHR secondary to hyperfiltration and fatty changes 
respectively.
It is well known that for the vast majority of biological systems an elevation in circulating 
hormone levels results in the down-regulation of that particular hormones biological 
response and that this is usually through a reduction in its receptor number. Certainly, in 
the healthy SD rat, it has beeil shown that there is a reduced response to elevated AVP at 
the ViaR and that this ViaR desensitisation is fast and accompanied by sequestration of 
receptors inside the cell (403). Previous studies have demonstrated, however, that in 
disease states an elevation in circulating AVP concentrations have variable and 
unpredictable effects on receptor regulation. In dehydration an elevated AVP is associated 
with down-regulation of renal V2 RS. (415). In DOCA-salt hypertension, an animal model
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of mineralocorticoid hypertension, increased circulating AVP levels are associated with 
down-regulation of liver Via and kidney V2 R.S and up-regulation of kidney ViaRs with 
interestingly no changes in mRNA levels seen. (120) In a 2 week normotensive model of 
DM an elevated plasma AVP was associated with down-regulation of both hepatic and
renal ViaRs with no alteration to the renal V2 R (51). Many studies, however, looking at
_
AVP receptor regulation, have used the AVP receptor antagonist H[AVP] that binds non- 
selectively to both the Via and V2 RS. Caution should thus be exercised when interpreting 
these studies. This problem highlights the necessity for studying individual receptor 
subtypes with selective and specific radioligands and for studying these receptors in 
specific animal models and individual tissues. Our group has available to us the selective 
ViAR antagonist, radiolabelled 125I[d(CH2 )s, sarcosine7]-AVP, and it was used throughout 
this study.
AVP receptors may show differential regulation in the more severe hypertensive 8 week 
diabetic model as compared to the previously studied 2 week normotensive model for a 
number of reasons. Initially down-regulation of receptors may simply be a regulatory 
negative feedback type response to high circulating AVP levels. However, as the disease 
progresses, the kidney sustains some damage, as evidenced by the development of 
microalbuminuria, and these regulatory responses are therefore likely to alter. Structural 
changes to the kidney may result in the cell surface V iaR ceasing to function as efficiently 
and consequently more receptor numbers being placed on the cell surface in a bid to 
compensate for this. The actual receptor binding domains remain unaltered and therefore 
Kd is unchanged whilst Bmax is increased.
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The increase in V iaR number could also serve a physiological purpose and thus be a 
“normal” regulatory response in trying to limit the excessive diuresis associated with DM.
The antidiuretic action of AVP mainly depends on V2 R-mediated effects in the renal 
collecting duct. Other actions mediated by the renal ViaR may also contribute either to 
reinforce or to blunt this antidiuretic action (160). A high level of AVP is sufficient to 
induce general ViAR-mediated vasoconstriction and could thus limit any excessive diuresis 
associated with DM, helping prevent dehydration (416). At lower AVP levels, selective 
vasoconstriction of central vasa recta causes a reduction in intramedullary blood flow, and 
thus also has a water sparing effect (135-137). On the other hand, studies have shown that 
ViAR stimulation in collecting duct activates prostaglandin synthesis and that these in turn 
reduce the V2 R-dependent stimulation of adenylate cyclase reducing the intensity of V2 R- 
mediated cellular effects (417). Physiologically, the activation of these collecting duct 
ViaRs may not play a role until higher plasma AVP levels and thus an antidiureses that is 
too intense may be avoided.
The up-regulation of the hepatic ViaR seen in this study may also have advantages to the 
diabetic patient. AVP stimulates hepatic urea synthesis and this effect is mediated through 
the liver ViaR (418). Such an up-regulation could improve urinary concentrating capacity 
by helping to provide more urea to the kidney. In vitro studies of perfused rat liver or 
isolated hepatocytes have however shown that AVP stimulates glycogenolysis and 
gluconeogenesis and with this up-regulation of hepatic ViaRs the metabolic effects of DM 
are therefore potentially accelerated (418).
Several explanations exist for the dissociation between changes in receptor numbers and 
mRNA expression in the 8 week, DM-SHR although all remain speculative. Firstly
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alterations in post-translational mechanisms such as internalisation and recycling may 
occur. Receptor-mediated endocytosis, by removing receptors from the cell surface, plays 
a role in desensitising target cells to subsequent exposure to hormone (419). Cell culture 
studies using Chinese hamster ovary cells and A-9 lung fibroblast cells transfected with the 
V iaR (420) or A-10 vascular smooth muscle cells expressing V iaRs (421), have shown 
that the AVP receptor-ligand complex is internalised into cells by receptor-mediated 
endocytosis. This process can be inhibited by AVP and also by hypertonic sucrose (420, 
421).
Alternatively, post-translational processing of AVP receptors may be responsible for the 
disparity between receptor numbers and mRNA expression in the hypertensive, diabetic 
model. Certainly glycosylation appears to be important for receptor trafficking of the V2R 
in LLC-PK-1 cells where inhibition of specific intracellular carbohydrate processing 
enzymes inhibits V2R biosynthesis and internalisation (422). To date the role of post- 
translational processing in the function or expression of the ViaR has not been 
demonstrated.
After 8 months of combined DM and hypertension the data available from study 2 
demonstrates an unaltered number and affinity of liver V iaRs while those in the kidney 
were significantly down-regulated. These differences in hepatic and renal gene expression 
over time most likely relate to the duration of the diabetic process although one cannot 
exclude that other factors, such as the severity of DM or low-dose insulin treatment, may 
also influence V iaR number and affinity. As described above, physiologically water 
conservation should take precedence early in the diabetic process. With more prolonged 
disease however, structural damage such as basement membrane thickening, glomerular
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hypertrophy and mesangial expansion (286) becomes increasingly severe and it makes 
sense that preservation of renal function and anatomy would become of higher priority. By 
analogy with angiotensin II and from the limited studies available using the non-peptide 
AVP receptor antagonists it can be inferred that AVP is likely to be deleterious when 
present long-term and in excess. For instance, a recent study in Brattleboro and control 
rats with STZ-DM demonstrated that urinary albumin excretion more than doubled in 
control animals but rose by only 34% in the Brattleboro-DM group (312). IV AVP has 
been shown to result in glomerular cell expansion via the over-expression of transforming 
growth factor beta-1 (TGF-P 1) and that this proliferative response is much enhanced in 
SHR as compared with normotensive controls (423). If an elevated plasma AVP results in 
the increased expression of cytokines then again by analogy to other systems such as the 
vascular endothelial growth factor (VEGF) and its receptor VEGF receptor 2, it is possible 
that these cytokines serve to down-regulate the expression of the renal V iaR (424). As 
TGF-P expression has been reported to increase in the kidney with duration of DM this 
would represent a likely candidate (425, 426). Indeed, a negative feedback role for 
increase TGF-p on the AVP system has been demonstrated in a couple of studies in rat. 
TGF-p has been show to block the acetyl choline stimulated release of AVP from the 
hypothalamus and amygdala where a variety of other cytokines failed to do so (427). In a 
separate study a 4 fold increase in mesangial cell TGF-p was seen with AVP stimulation 
and this increased concentration of growth factor in turn inhibited the cellular signalling of 
AVP at a stage prior to phospholipase C activation. Whether this inhibition was effected at 
the V iaR level or at a more distal point in the signalling pathway was however not clear as, 
although receptor numbers appeared unchanged, their number was determined using the 
non selective ViR agonist [3H]AVP (428).
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In long term DM, as structural damage in the diabetic liver is limited primarily to fatty 
change, it makes sense that no significant differences in the ViaR over control SHR was 
seen in this organ.
The preliminary data presented from study 3 would suggest that, as compared to the 
findings presented in chapter 4 in non-diabetic SHR, dual ACE and V iaR antagonism does 
have a role to play in lowering BP in the diabetic hypertensive animal. This would make 
sense in light of the findings in this chapter of an up-regulated V iaR system in DM.
In conclusion, in a rat model that combines DM and hypertension, increased levels of 
plasma AVP are associated with up-regulation of the hepatic and renal V iaRs with no 
significant change in affinity of the hepatic and renal V iaRs for AVP. This study is the 
first to show this and suggests a rationale for the use of V iaR blockade in DM.
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Chapter 6: General discussion and future directions 1M
In this concluding chapter the major findings of this thesis will be drawn together and the 
broader applications of these, in terms of the place of vasopressin (AVP) receptor blockade 
and further study of the AVP system in cardiovascular disease (CVD), discussed.
6.1 GENERAL DISCUSSION AND FUTURE DIRECTIONS
The characterisation of an orally effective dual Via and V2  receptor (Via and V2 R) 
antagonist, drug A, was described in chapter 3. This drug had undergone little previous 
research and was demonstrated here to interact reversibly and competitively at the hepatic 
ViAR and renal Via and V2 R sites in Sprague Dawley rat. Drug A remained metabolically 
active after 5 days of continual dosing but its aquaretic response was diminished.
To assess the potential clinical usefulness of this drug a longer-term metabolic study 
should be undertaken to look into the possibility of continuing drug tachyphylaxis and 
ultimately lack of any clinical effect of drug A. Currently one of the most promising 
clinical indications for the prescription of a mixed AVP receptor antagonist is in the 
treatment of heart failure where elevated plasma AVP contributes to increased vascular 
resistance through its ViaR and to fluid retention via its effects at the V2 R. As described 
previously, YM087 or conivaptan is a mixed non-peptide V 1A/V2 R antagonist that has 
shown great promise thus far as a treatment for congestive cardiac failure in animal models 
and humans (265, 266). Our group has the experimental expertise to induce myocardial 
infarction in rats (41,429) and a 4 week study to look at the effect of oral administration of 
drug A on cardiovascular end points within this model will shortly be undertaken. It must 
be remembered that in order to put into perspective any findings from the study of AVP 
receptor antagonists, there is considerable inter-species variation in drug responses (249). 
YM087 is not however subject to the same species heterogeneity that affects these other
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AVP receptor antagonists (383). Drug A has thus far undergone little research in any 
species other than rat and caution should be exercised when trying to interpret findings 
from any such future studies.
Chapter 4 reported on the combination treatment of ACE inhibitor ramipril with V iaR 
blocker OPC 21268 in the adult spontaneously hypertensive rat (SHR). No additive 
hypotensive effects were seen with the combination treatment and OPC 21268 alone did 
not lower blood pressure (BP) over hypertensive control. This was the first study to look 
at combination ACE and V iaR antagonist treatment in an adult model of essential 
hypertension where plasma AVP was not elevated. Although a negative study it is 
important to understand that the addition of ViaR antagonism to ACE inhibition does not 
have a therapeutic role to play in this particular clinical setting. This is unlikely to be the 
case, however, in hypertension associated with low plasma renin levels, such as is seen in 
African-Americans, renal failure patients, the elderly and diabetics. Indeed a pilot study in 
a rat model combining hypertension with diabetes mellitus (DM) did show additive BP 
lowering effect with both treatments. This is described in detail in chapter 5.
Future studies should aim to look for any additive effects of these treatments in those cases 
of low renin hypertension, for instance in renal failure, a rat model that has been used with 
success in our group (267).
The effect on the AVP system of 8 weeks of streptozotocin induced DM (STZ-DM) in 
SHR was reported in chapter 5. In the context of an elevated AVP, a normal finding in 
DM, an up-regulation of the V iaR, both in liver and kidney, was seen. This was manifest 
as an increase in receptor density with no associated increase in affinity of the receptor for
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the ViaR specific radioligand 125I-labelled [d(CH2 )5 ,sarcosine7]AVP being seen. This up- 
regulation of receptor protein density was observed despite normal renal and hepatic ViaR 
mRNA levels. This study was the first to describe the up-regulation of the ViAR in DM 
and contrasts with a previous study from our group that demonstrated hepatic and renal 
ViaR down-regulation using a 2 week normotensive model of STZ-DM (51). Normally in 
biological systems when the concentration of a receptor ligand is increased then the cell 
surface receptors for that particular ligand are subsequently down-regulated in a bid to 
“keep things in balance”. A number of possible explanations exist for the apparent 
disregulation of the AVP system seen in this hypertensive model of DM but all of them 
remain speculative at this time. These are discussed in more detail in chapter 5. Briefly, in 
the relatively severe model of 8 weeks of DM combined with hypertension, where renal 
damage has been sustained (in this case as evidenced by albuminuria), then secondary to 
structural and functional damage, normal regulatory responses are no longer seen. In the 
previous study, using the 2 week normotensive rat model of DM, very little structural or 
functional damage, if any, would be expected. In humans, the prevalence of hypertension 
is 1.5 to 2 times greater in people with DM as compared to matched non-diabetic 
individuals (12). An animal model, therefore, that incorporates both could be seen as more 
relevant to the clinical situation. This observed disregulation may serve a physiological 
purpose and thus be a “normal” regulatory response in trying to limit the excessive diuresis 
associated with DM. Many of the actions of AVP at the ViaR, both in the kidney and to a 
lesser extent perhaps in the liver, are to reinforce or blunt the antidiuretic action mediated 
via the V2 R. It is known that the poorer the diabetic control then the higher the plasma 
AVP concentration (321) and I propose that at lower AVP concentrations more ViaRs are 
recruited to assist in water retention. These receptors are located in the vasa recta and 
selective vasoconstriction of these arteries causes a reduction in intramedullary blood flow
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and thus a water sparing effect (135-137). Higher AVP concentrations, associated with 
poorly controlled DM, may see the physiological activation of collecting duct ViaRs (117). 
These are known to blunt the V2 R dependent production of cyclic adenosine 
monophosphate and would thus help limit any excessive water retention that might be 
expected as AVP levels climb and its antidiuretic action continues unchecked (417, 430).
Several explanations for the dissociation between changes in receptor number and mRNA 
expression in DM exist. These include alterations in post-translational mechanisms such 
as internalisation and recycling via receptor-mediated endocytosis (419). Alternatively, 
post-translational processing of AVP receptors has been proposed to explain the disparity 
between the receptor number and mRNA expression observed in chapter 5. Some previous 
studies have indicated that post-translational events such as glycosylation (422, 431) may 
be important for receptor trafficking and /or biosynthesis and internalisation and this may 
be particularly relevant here.
The limited information gained from an 8 month pilot study of STZ-DM in SHR would 
suggest that after a more prolonged period of DM, combined with hypertension, then the 
V iaR numbers in liver and kidney are no longer up-regulated but are equivalent to that of 
hypertensive control rats. Therefore it may be that the up-regulation of the V iaR system 
has a role to play early on in the natural history of this disease. Unusually, however, in this 
study the plasma AVP levels were not elevated in the DM-SHR as compared to SHR.
A second pilot study looked at the effect of combination ACE inhibition with V iaR 
antagonism on BP and demonstrated an additive hypotensive effect, a finding not 
previously seen with non-diabetic SHR (as described in chapter 4). This would make
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sense in light of the findings from chapter 5 where elevated plasma AVP is associated with 
up-regulation of the V iaR in the DM-SHR as compared to the non-diabetic SHR and thus 
the blocking of an up-regulated system provides clinical benefit.
Future studies would aim to look at the V2 R and whether it too is up-regulated in this 
particular animal model.
It would be beneficial to study the second messenger systems for both receptors as it is 
feasible that while receptor numbers are up-regulated their cell signalling pathways are not. 
Localisation studies to determine where in the kidney ultrastructure these up-regulated 
V iaRs can be found would aid our understanding of the purpose these receptors might 
serve in this disease model.
A time course experiment over at least 8 months with animals being sacrificed at various 
stages would provide information on the regulation of the AVP system over time in DM 
and hypertension. This would guide our understanding as to when AVP receptor blockade 
would be of most benefit in the treatment of this disease. Information gained so far would 
suggest that early blockade of an up-regulated V iaR system would provide greatest clinical 
benefit.
The most important study to be undertaken is an intervention study and this is currently 
planned for within our laboratory. This will be an 8 week study. SHR are to be made 
diabetic at 8 weeks of age and randomised to receive vehicle, OPC 21268, ramipril or 
combination ramipril and OPC 21268. BP will be measured every 2 weeks, urinary 
albumin excretion every 4 weeks and all metabolic, hormonal and biochemical parameters,
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as well as tissue weights, will be determined at sacrifice. It is hoped that the treated DM- 
SHR will, most importantly, demonstrate a reduction in urinary albumin excretion, BP and 
tissue weights and that the combination of ramipril and OPC 21268 will be additive in this 
regard.
6.2 GENERAL CONCLUSION
In conclusion, the studies reported in this thesis have attempted to enhance our 
understanding of the role of AVP and its V iaR system in the CVDs of hypertension and 
DM. New treatments are continually being sought in a bid to improve morbidity and 
mortality in people with these conditions. Non-peptide AVP receptor blockers are looking 
increasingly promising as an additive treatment to existing drugs such as ACE inhibitors. 
From this thesis it seems likely that they will have a particularly exciting future in those 
CVDs associated with an elevated AVP such as DM.
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